CA2194493A1 - Compositions and methods for a bioartificial extracellular matrix - Google Patents

Compositions and methods for a bioartificial extracellular matrix

Info

Publication number
CA2194493A1
CA2194493A1 CA002194493A CA2194493A CA2194493A1 CA 2194493 A1 CA2194493 A1 CA 2194493A1 CA 002194493 A CA002194493 A CA 002194493A CA 2194493 A CA2194493 A CA 2194493A CA 2194493 A1 CA2194493 A1 CA 2194493A1
Authority
CA
Canada
Prior art keywords
hydrogel
seq
nerve
agarose
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002194493A
Other languages
French (fr)
Inventor
Ravi V. Bellamkonda
John P. Ranieri
Patrick Aebischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2194493A1 publication Critical patent/CA2194493A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005Ingredients of undetermined constitution or reaction products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/043Proteins; Polypeptides; Degradation products thereof
    • A61L31/047Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/32Materials or treatment for tissue regeneration for nerve reconstruction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813Carrier is a saccharide

Abstract

Methods and compositions for a bioartificial 3-D extracellular matrix, wherein the matrix is derivatized with at least one ECM adhesion molecule or adhesive peptide fragment thereof.

Description

W096l02286 P~
21~93 COMPOSITIONS AND MET~ODS
FOR A ~IOARTIFICTA~ E~TRA~T~TTTTTAR MAT

Field of the Invention This invention relates to compositions and methods for a bioartificial extracellular matrix.

Backaround of the Invention Tissue engineering in the nervous system deals with the functional replacement of damaged tissues and nervous system regeneration.
The ability to organize cells in three dimensions (3-D) is an important component of tissue Pnqin~ring. The behavior of cells is influenced both by their intrinsic genetic programs and their extracellular environment. The extracellular environment includes 'passive' structural - ~nts and biologically 'active' components.
Most cells in multic llulAr organisms are in contact with an intricate meshwork of interacting, extracellular macromolecules that constitute the extrAc~llulAr matrix (ECM). These macromolecules, mainly proteins and polysaccharides, are secreted locally and assemble into an organized 3-D meshwork in the extracellular spaces of most tissues. ECM
moleculos include glycosA~;noglycans, and proteoglycans such as chrondroitin sulfate, fibronectin, heparin sulfate, hyaluron, dermatan sulfate, keratin sulfate, W096~02286 ~ ~ - 2 -laminin, collagen, heparan sulfate ~roteoglycan, and elastin. In addition to serving~as a universal biological glue, ECM moleculès also form highly sp~ciAli7ed structures such as cartilage, tendons, basal laminae, and (in conjunction with secondary deposition of calcium phosphate) bone and teeth.
Alberts et al., Molecular BioloqY of the Cell Garland, NY, pp. 802-24 (1989).
Extracellular matrices modulate the organization of the intracellular cytoskeleton, cell differentiation and the spatial architecture of cells and tissues. In fact, the EC~ plays a critical role in regulating the behaviour of cells that contact it by influencing cellular development, migration, proliferation, differentiation, shape, polarity and metabolic function.
Several peptide active sites responsible for cell attl~hr-~t have been identified in various ECM
molecules.
In vivo, laminin (LN) immunoreactivity has been detected in several regions of the embryo including muscles (Chui and Sanes, Dev. Biol., 103, pp. 456-67 (1984)), spinal cord (Azzi et al., ~3~Li_, 9, pp. 479-85 (1989), spinal roots (Rogers et al., Dev. Biol., 113, pp. 429-35 (1986)), optic nerve (~cLoon et al., J. Neurosci., 8, pp. 1981-90 (1988)), cerebral cortex (Liesi, E~, 4, pp. 1163-70 (1985);
Zhou, Dev. Brain Res., 55, pp. 191-201 (1990)), hippO c (Gordon-Weeks et al., J. Neurocvtol., 18, pp. 451-63 (1989)) and the medial longitudinal f~cci~ c of the midbrain (Letourneau et al., DeveloPment, 105, pp. 505-19 (1989)).
The tripeptidic sequence RGD (ArgGlyAsp;
AA2-AA4 of SEQ ID N0:2) has been identified to be responsible for some of the cell adhesion properties of ~ W096/02286 2 1 ~q 4 ~ 9 3 ~ C.2~
:

fibronectin (piersrhhacl~pr and Ruoslahti, Science, 309, pp. 30-33 (1984)), laminin (Grant et al., ~çll, 58, pp. 933-43 (1989)), entactin (Durkin et al., J. Cell.
Biol., 107, pp. 2329-40 (1988~), vitronectin (suzuki et al., EMB0, 4, pp. 2519-24 (1985)), collagen I
(Dedhar et al., J. Cell. Biol., 107, pp. 2749-56 (1987)), collagen IV (Aumailley et al., Ex~. Cell Res., 187, pp. 463-74 (1989)), thrombospondin (Lawler et al., J. Cell. Biol., 107, pp. 2351-61 (1988)) and tenascin (Frie~l~ndt~r et al., J, Cell. Biol., 107, pp. 2329-40 (1988)) The sequence YIGSR (TyrIleGlySerArg; AA5-AAg of SEQ ID N0:1), found on the Bl chain of laminin, promotes epithelial cell attachment (Graf et al., Biorht~mistry, 26, pp. 6896-900 (1987)) and inhibits tumor metastasis (Iwamoto et al., Science, 238, pp. 1132-34 (1987)).
The IKVAV sequence found on the A chain of laminin, has been reported to promote neurite outgrowth (Tashiro et al., J. Biol. Chem., 264, pp. 16174-182 (1989); Jucker et al., J. Neurosci. Res. 28, pp. 507-17 (1991)).
All of the studies using these peptidic sequences of cell attachment and neurite promotion were con~lrtPd on flat two-dimension substrates (Smallheiser et al., Dev. Brain Res., 12, pp. 136-40 (1984); Graf et al., Bioc~mistrv~ 26, pp. 6896-900 (1987); Sephel et al., Biochem. Bio~hYs~ Res~ c~ ., 2, pp. 821-29 (1989); Jucker et al., J. Neurosci. Res., 28, pp. 507-17 (1991)). The physical and chemical nature of theoulture substrate influences cell attachment and neurite extension. The physical microstructure of a 2-D culture substrate can influence cell behavior. The use of permissive and non-permissive culture surface chemistries facilitates nerve guidance in 2-D. The _ ... _ . . _ _ . _ . . . . _ . . _ _ _ _ _ _ _ . . ..

W096l02~6 ~ r r vl,Lv,~

cell attachment regulating function of various serum proteins like albumin and fibronectin is dependent on the chemistries of the culture substrates that they are adsorbed onto.
Gene expression is reported to be regulated differently by a flat 2-D substrate as opposed to a hydrated 3-D substrate. For example, monolayer culture of primary rabbit articular chondrocyte and human epiphyseal chundLo~yLe on 2-D tissue culture substrates causes primary chondrocyte to lose their differentiated phenotype. The differentiated chundLuuy~e phenotype is re-expressed when they are cultured in 3-D agarose gels (Benya and Shaffer, Ççll, 30, pp. 215-24 (1982);
Aulthouse, et al., In Vitro Cell Dev. Bio., 25, pp. 659-68 (1989)).
Similarly, alkaline phosphatase gene expression in primary bile ductular epithelial cells is differentially regulated when they are cultured in 3-D
Matrigel~, collagen I or agarose gels as opposed to 2-D
cultures (Mathis et al., Cancer Res., 48, pp. 6145-53 (1988)).
Therefore, 3-D presentation of ECM components may better mimic the in v vo environment in influencing cell or tissue response. In particular, in vivo use of ECM biomolecules may require such a 3-D system for optimal efficacy. The development of a defined, bioartificial 3-D matrix that presents ECM molecules, or active portions thereof, would facilitate tissue engineering in the nervous system by allowing in vitro and in vivo cell manipulation and cell culture in 3-D.
See, e.g., Koebe et al., Crvobioloqv 27, pp. 576-84 (19go) .
In addition, there is a need to develop a defined, biosynthetic matrix, because the tumorogenic origins of some commercially available ECM, e.g., W096/02286 2 l g A ~ 9 ~ 1/. s ~

Matrigel~ mouse sarcoma derived ECM, render it unattractive for some n vitro and in vivo applications. Further, naturally occuring ECM
~nts such as collagen may be enzymatically degraded in the body while a synthetic ECM is less likely to be degraded.
-ry of the Invention This invention provides a three-dimensional hydrogel based, biosynthetic, extracellular matrix (ECM) equivalent, and method of making same. Agarose matrices having a chemistry amenable to derivatization with various ECM adhesive peptides and proteins, are preferred in forming the 3-D hydrogel substrates of this invention. These biologically active 3-D
templates may be useful in facilitating tissue regeneration or replacement.

Brief Descri~tion of the Drawinqs Figure 1. A double Y-axis plot depicting the influence of agarose gel concentration on average pore radius (Y1) and percent striatal cells extending neurites (Y2) after 72 hours in culture. Pore radius was calculated by hydraulic permeability measurements of the different gel concentrations. Solid line through pore radii data points is an exponential fit with r2=0.985.
Figure 2. Schematic of an agarobiose unit and the carbonyld;;mid~7ole coupling chemistry for the immobilization of CDPGYIGSR (CysAspProGlyTyrIleGly SerArg; SEQ ID N0:1) oligopeptide to agarose gels.
Figure 3. Histogram depicting E9 chick DRG
neuritic spread as the ratio of total ganglionic spread area/ganglionic cell body area (TGSA/GCBA). Neuritic spread in various gels is plotted as a percentage of W096l02286 21 9 4 4 ~ 3 -~ j r neuritic spread in Ag-Plain gels at 2 days (n=6).
Error bars represent standard deviation. '*' depicts a statistically significant higher neuritic spread (p<0.05) relative to Ag-Plain; '#' depicts a statistically significant lower neuritic spread (p<0.05) relative to Ag-Plain.
Figure 4. Histogram of comparative E9 Chick DRG neurite extension in underivatized and derivatized agarose gels (n=6). Error bars represent standard deviation. '*' denotes a statistically significant, higher neurite length (p<0.05) compared to Ag-Plain;
'#' denotes a statistically significant lower neurite length (p<0.05) compared to Ag-Plain.
Figure 5. Histogram depicting comparative PC12 neuritic extension in underivatized and derivatized agarose gels (n=6). Error bars represent standard deviation. '*' depicts a significant difference with respect to Ag-Plain (p<0.05); '#' depicts a significant difference with respect to all other LN oligopeptide derivatized agarose gels (p<0.05)-Figure 6. Schematic illustration of dorsal root regeneration across a nerve gap of 4.0 mm with a nerve guidance channel whose lumen is loaded with agarose gel.
Figure 7. Graph showing the number of myelin~ted axons regenerated at 4 weeks along polymer guidance ~h~nn~l~ filled with AgPlain and Ag-CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) gels. "*"
depicts a statistically significant difference with p < 0.05 using the Student t test.
Figure 8. Graph showing the density of myelinated axons regenerated at 4 weeks along polymer guidance channels filled with AgPlain and Ag-CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) gels. "*"

~ W096/02286 ~g 4 ~ ~ 3 - , P~

depicts a statistically significant difference with p < 0.05 using the Student t test.
Figure 9. Histogram depicting the number of myelinated axons in regenerating sural nerves at 2.0 mm distance from the proximal nerve stump in polymer guidance chAnnplq filled with A) saline; B) AgPlain and C) Ag-CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ ID
N0:1). "*" depicts a statistical difference of p < 0.05 when compared to saline or AgPlain. Student t test was used to evaluate statistical significance.
Figure 10. Histogram depicting the density of myelinated axons in regenerating sural nerves at 2.0 mm distance from the proximal nerve stump in polymer guidance rh~nnr~lc filled with A) saline; B) AgPlain and C) Ag-CDPGYIGSR (CysAspProGlyTyr~leGlySerArg; SEQ ID
N0:1). "*" depicts a statistical difference of p < 0.05 when compared to saline or AgPlain. Student t test was used to evaluate statistical significance.

Detailed Descri~tion of the Inventisn This invention provides a oiosynthetic, hydrogel-based, three-dimensional bioartificial ECM.
The bioartificial extrac~ r matrices of this invention offer the possibility of r~n;p~ ting cells in 3-D, and may be used as three dimensional templates for tissue r~nginPrring efforts Ln Yi~L~ and ~n v vo.
The term "nerve" means both nonfascicular and polyfascicular nerves.
The term "active factor" or "growth factor"
includes any active analogs, active fragments, or active derivatives thereof.
Any suitable hydrogel may be used as the substrate for the bioartificial extracellular matrices of this invention. Compositions that form hydrogels fall into three classes. The first class carries a net WO 96/02286 2 1 9 4 ~ 9 3 r~
~ 8 ~

negative charge (e.g., alginate). The second class carries a net positive charge (e.g., collagen and laminin). Examples of commercially available extracellular matrix rn~rrnPnt hydrogels include Matrigel~ and Vitrogen~. The third class is net neutral in charge (e.g., highly crosslinked polyethylene oxide, or polyvinylalcohol).
A hydrogel suitable for use in this invention is preferably a defined polymer, most preferably a polymer that is synthetic or can be prepared from a naturally occurring, non-tumorigenic source, free of undesired biological (e.g., bacterial or viral), chemical or other contaminants. Most preferred as the matrix substrate are well characterized hydrogels that permit presentation of only the desired ECM adhesion molecule or dhesive peptide fragement in 3-D, 6ubstantially free of undesired adhesion motifs.
Matrigel~ is not a defined substrate and also less desirable since it is derived from a murine sarcoma line. In addition, not alI synthetic polymer hydrogels are suitable. For example, the use of acrylic based hydrogels by Woerly et al., Cell Trans~lantatign, 2, pp. 229-39 (1993) presents the possibility of cytotoxicity because entrapment of neuronal cells is done concomitantly with the cross-linking reaction in the presence of free radical initiators.
Polymers that may be useful as hydrogel matrix substrate materials include high molecular weight polyethylene oxide (PE0) and hyaluronate.
Stabilized hyaluronate is commercially available (Fidia Advanced Biopolymers). Various PE0 polymers are also commercially available.
Polysaccharides are a class of macromolecules of the general formula (CH20)n which are useful as the ~ W096/02286 ~ t ~ 5~
21g4~3 _ g _ hydrogel substrate in the present invention.
Polysaccharides include several raturally occuring compounds, e.g., agarose, alginate and chitosan. We prefer agarose.
Agarose is a clear, thermoreversible hydrogel made of polysaccharides, mainly the alternating copolymers of 1,4 linked and 3,6-anhydLo ~ L-galactose and 1,3 linked ~-D-galactose. Two commercially available agaroses are SeaPrep~ and seaPlaque~ agarose (FKC Corp. Rockland, Maine). SeaPrep~ is a hydLoxyethylated agarose that gels at 17~C. The particular suitability of a hydrogel as a biomaterial stems from the similarity of its physical propertiefi to those of living tissues. This resemblance is based on its high water content, soft rubbery consistency and low interfacial tension. The theL-moreversible properties of agarose ge]s make it possible for agarose to be a liquid at room temperature allowing for easy mixing of cell-gel solution and then cooling to 40C
causes gelation and entrapment of cells. This is a comparatively benign process, free of ~h~mic~lq toxic to the cells.
We prefer an agarose concentration of 0.50 to 1 25~ (w/v), most preferably 1.0%, for the permissive layers of the hydrogel matrix.
Several physical properties of the hydrogel matrices of this invention are dPp~nd~nt upon gel concentration. Increase in gel concentration may change the gel pore radius, morphology, or its permeability to different molecular weight proteins.
Gel pore radius determination can be det~rmined by any suitable method, including hydraulic permeability determination using a graduated water column, transmission electron microscopy and sieving spheres of known radius through different agar gel W096/02286 21~ 4 4 9 3 r~ JS~

concentrations. See, e.g., Griess et al., Bio~hvsical J., 65, pp. 138-48 (1993). We prefer hydraulic permeability-based pore radius determination, as the method most sensitive to changes in gel concentration.
Measurement of gel hydraulic permeability using a graduated water column enabled the calculation of average pore radius for each of the gel concentrations studied. The average gel pore radius fell exponentially as the gel concentration increased.
The slope of the curve indicated the sensitivity of pore radius to gel concentration. The average gel pore radius preferably varies between 120-290 nm, and is most preferably approximately 150 nm. The pore radius of the 1.25% threshold agarose gel concentration was 150 nm.
The agarose hydrogels of this invention may be used as a carrier to present various ECM proteins or peptides, e.g., laminin fibronectin, and/or their peptidic analogs in 3-D. The chemistry of agarose permits easy modification with such ECM adhesive proteins and/or peptides. We prefer covalent immobilization of ECM proteins to the hydrogel h l~hon~ . Such immobilization is important because the physical blending of low molecular weight oligopeptides with hydrogels will not retain the peptides in the gel.
Further, covalent immobilization prevents the possible saturation of cell surface receptors by 'free-floating' ECM molecules in hydrogel-ECM molecule blends.
Any suitable coupling system may be used for derivatization. Most preferably, covalent coupling using a bi-functional imidazole coupling agent, e.g., 1'1 carbonyldiimidazole, is used. This coupling chemistry does not alter the physical structure of the gel significantly.

W096/02286 ~ ~I/Uv~ O~

The bioartificial hydrogel extracellular matrices of this invention are useful for presenting in 3-D full length extracel]ular matrix proteins involved in cell adhesion. In addition, peptide fragments of such adhesion molecules that contain cell binding sequences may also be used (i.e., adhesive peptide fragments). Several such adhesive peptide fragments are known in the art. A particular peptide fragment can be tested for its binding ability or adhesive capacity according to standard techniques.
The bioartificial hydrogel matrices of this invention can be used to present ECM adhesion molecules, or adhesive peptide fragments thereof, in 3-D to a variety of cell types. These cell types include any cell that is normally in contact with the ECM in v vo, or any cell bearing a cell surface receptor capable of binding to an ECM adhesion molecule or adhesive peptide fragment thereof.
Useful cells include epithelial cells, endothelial cells, fibroblasts, myoblasts, chondroblasts, osteoblasts, and neural stem cells (Richards et al., ~ 89, pp. 8591-95 (1992); Ray et al., PNAS 90, pp. 3602-06 (1993)). Other cells that may be useful in the methods and compositions of this invention include, Schwann cells (Wo 92/03536), astrocytes, oligodendrocytes and their precursors, adrenal chromaffin cells, and the like.
Stem cells represent a class of cells which may readily be ~Yp~n~ed in culture, and whose progeny may be terminally differentiated by the administration of a specific growth factor. See, e.g., Weiss et al.
(PCT/CA 92/00283).
Myoblasts are muscle precursor cells originally derived from mesodermal stem cell populations, e.g., L-6 and ~-C~3 cells. Primary W096/02286 2 1 9 ~ ~ 9 3 - ~ .IL~ ~

myoblasts can be readily isolated from tissue taken from an autopsy or a biopsy, and can be purified and ~Yp~n~. Myoblasts proliferate and fuse together to form differentiated, multi-nucleated myotubes.
Nyotubes no longer divide, but continue to produce muscle proteins. While proliferating, myoblasts may readily be genetically engineered to produce therapeutic molecules. Myoblasts are capable of migrating and fusing into pre-existing fibers.
It will be appreciated that the choice of ECM
adhesion molecule or adhesive peptide fragment for use in the bioartificial ECM matrix will depend upon the desired target cell type. See, e.g., Kleinman, United States Patent 4,829,0Q0; End and Engel, "Multidomain Proteins Of The Extracellular Matrix And Cellular Growth", in McDonald and Mecham Biolo~v of Extracellular Matrix Series, Academic Press, NY, pp. 79-129 (1991). One of skill in the art can routinely assay any particular ECM molecule or adhesive peptide fL t motif for its adhesive capacity for a chosen cell type.
Thus, according to the compositions and methods of this invention, it may be possible to influence the behavior (i.e., development, migration, proliferation, differentiation, shape, polarity, and/or metabolic function) of any ECM-responsive cell type, by providing the appropriate ECM-mediated molecular cues.
In some embodiments, the hydrogel ECM matrix can be derivatized with the appropriate ECM adhesion molecules or adhesive peptide fragments and implanted into a desired location in a host, e.g., a mammal, preferably a human. In these ~mho~;r~nts, the matrix acts as a support for tissue regeneration, whereby the host cells infiltrate the matrix. In the presence of ~ W096l02286 ~L 9 ~ 4 9 ~ .~L

the appropriate 3-D molecular cues in the matrix host tissue regeneration is facilitated.
Such embodiments have use, for example, in cartilage or tendon regeneration by derivatizing the matrix with ECM adhesion molecules or adhesive peptide fragments that favor chondrocyte invasion. Similarly, the matrices of this invention may be useful in promoting muscle, bone or skin regeneration by presenting the appropriate molecular cues to influence myoblast, osteoblast or epithelial cell behavior. In a preferred Pmho~ir~nt~ the bioartificial matrices of this invention are used to promote nerve regeneration, in nerve guidance channels.
In other ~mho~i~~nts, the bioartificial matrices of this invention can be pre-seeded with cells, whereby the cells are suspended in the matrix and exposed to the appropriate molecular cues in 3-D.
These cell-seeded matrices are useful in tissue replacement protocols. According to these ~mhQ~ir-nts, tissue can be reconstituted i ~tro and then implanted into a host in need thereof. FOL- example, cardiac myoblasts may be sllcp~n~d in the derivatized hydrogel matrices of this invention to create a tissue patch of a thickness ~uLL~ on~ing to the cardiac wall. The reconstituted cardiac patch could then be implanted, as part of a tissue replacement therapy.
Similar protocols for cartilage, tendon, bone, skin, nerve, blood vessels and other tissues are contemplated. The ability to cast hydrogels, e.g., agarose, into a variety of shapes, as well the ability to fabricate "permissive" gel concentrations enables the production of bioartificial matrices that can influence cell behavior in defined planes or through defined "tracts".

W096/02286 2 ~ 9 4 ~

It will be appreciated that according to the foregoing ~mho~ir?nts~ the cells may be xenografts, allografts or autografts, preferably allografts, most preferably, autografts. Surgical procedures for implanting such cells are known. See, e.g., Gage, United States Patent 5,082,670.
In other Pmho~irants it may be desirable to ~nrArsnlate the cell-seeded matrix in a semi-permeable membrane to form a bioartificial organ. Such bioartificial organs are well known in the art. See, e.g., W0 92/019195, incorporated herein by reference.
In these ~mho~ nts the metabolic function of the onc~rs~llated cells may be controlled by the ECM
adhesion molecule or adhesive peptide fragment presented in 3-D. The encapsulated cells can be influenced to produce a biologically active molecule that may function within the encapsulated cells, or be released or secreted from the encapsulated cells, to exert a therapeutic effect on the host. This allows precise control over cell behaviour at a fixed location in the host body.
In a preferred orho~ nt, laminin-derived oligopeptidic fragments, an RGD-containing sequence (ArgGlyAsp; AA2-AA4 of SEQ ID N0:2), a YIGSR-containing sequence (TyrIleGlySerArg; AA5-AAg of SEQ ID
N0:1) and/or an IRVAV-containing sequence (IleLysValAlaVal; AA11-AA15 of SEQ ID N0:3), are coupled to the hydroxyl backbone of agarose, using any suitable method. Most preferably, the oligopeptidic fragments GRGDSP (GlyArgGlyAspSerPro; SEQ ID N0:2), CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1), or the l9-mer water-soluble amino acid sequence CSRARKQAA~TKVAVSADR (CysSerArgAlaArgLysGl nAl AAl AC~r IleLysValAlaValSorAlA~cr~rgi SEQ ID N0:3) are used.

W096l02~6 ~ s ~ .2 CDPGYIGSR (CysAspProGIyTyrIleGlySerArg; SEQ
ID NO:1) has been shown to evoke only 30% of the maximal response obtained by laminin in chemotactic functions with ~- ] ~nrr~ cells (Graf et al., Biochemistrv, 26, pp. 6896-900 (1987)). Thus, the use of full length ECM molecules may elicit more significant cellular effects. However, the use of minimal oligopeptides creates a more stringent substrate condition and facilitates the testing of the gel system without the potent biological effects of full length proteins eclipsing the gel's physical effects. This enables the development and testing of a system with a base physical structure to support cell viability and influence cell behaviour. The hydrogel matrix can then be rendered progressively more permissive by the use of appropr$ate covalently-coupled cell adhesion or extracellular matrix molecules.
The 3-D matrices of this invention may be further modified, preferably chemically modified, to include h~ncAmine residues. Ca~bol.yd~ates may be involved in cell adhesion. Dodd and Jessel, J. Exp.
~iQl~, 124, Oo. 225-38 (1986).
In another preferred ~mho~ir-nt, the compositions of this invention may be used in neural cell transplantation. The ability of biosynthetic hydrogels to organize, support and direct neurite extension from neural cells may also be useful for applications such as 3-D neural cell culture and nerve regeneration. The bioartificial extracellular matrices of this invention may potentially carry one or more of the several cell adhesion molecules that have been identified to play an important role in cell migration and neurite extension in the developing nervous system, including N-CAM and Ng-CA~ (Crossin et al., Proc. Natl.
Acad. Sci., 82, pp. 6942-46 (1985); Daniloff et al., 219411g3' ~ '' ' 7 ~' W096/02286 i~

J. Neurosci., 6, pp. 739-58 (1986)), tpn~in (Wehrle et al., Develo~ment l990, pp. 401-15 (1990)) and L1 (Nieke and Schachner, Differentiation, 30, pp. 141-51 (1985)). Among extracellular matrix glycoproteins, laminin has been shown to be one of the most potent inducers of neurite outgrowth n vitro. It is a ~ of the Schwann cell basal lamina and is thought to be involved in axonal regeneration n vivo (Baron-Van-Evercooren et al., J. Neurosci. Res., 8, pp. 179-93 (1983); Manthorpe et al., J. Cell. 8iol., 97, pp. 1882-90 (1983); Rogers et al., Dev. 8iol., 113, pp. 429-35 (1983).
LN has also been found to enhance attachment of many neural cell types (McCarthy et al., ~. Cell.
Biol., 97, pp. 772-77 (1983); Liesi et al., J. Neurosci, Res., 11, pp. 241-51 (1984); Hammarback et al., J. Neurosci. Res., 13, pp. 213-20 (1985);
Kleinman et al., Annals NY Acad. Sci., 580, pp. 302-10 (1990), increase the survival of sympathetic and septal neurons (Edgar et al., EM~0, 3, pp. 1463-68 (1984);
Pixley et al., J. Neurosci. Res., 15, pp. 1-17 (1986), and stimulate neurite outgrowth in many peripheral and central neurons (Baron Van EV~L~OO' ~n et al., J. Neurosci. Res., 8, pp. 179-93 (1983); Manthorpe et al., 3. Cell. 8iol., 97, pp. 1882-90 (1983); Rogers et al., Dev. Biol., 113, pp. 429-35 (1983); Steele et al., J. Neurosci. Res., 17, pp. 119-27 (1987).
LN and other ECM constituents influence neuronal development in both the peripheral and the central nervous systems. Hence, presenting ECM-oligopeptide derivatized agarose gels to the regenerating environment in 3-D may enhance nerve regeneration when introduced in appropriate animal models.

219 ~1~ 9 3 W096/02286 ,~,/ L~.~. .

~ he complex glycoprotein and proteoglycan , , ~nts of the extracellular matrix are thought to provide permissive pathways for neural cell migration and neurite extension during development. Cell-cell S and cell-extracellular matrix (ECM) interactions appear to regulate various aspects of neuronal cell differentiation including neural cell migration and neurite extension. Sanes, Ann. Rev. Neurosci., 12, pp. 491-516 (1989).
Anatomical studies of neural development show that the migratory pathways of pioneer neurons seem to consist of a 3-D ECM that is organized into a network of fibrils and granules. The ~hr~ LLopic attraction of neuronal growth cones from their target areas, coupled with a permi Cciye three dimensional maze comprised of ECM molecules like laminin (LN) and fibronectin (FN) and some cell free spaces filled with highly hydrates hyaluronic acid, is thought to play an important role in the development of embryonic nervous system.
Laminin (LN), an ECM molecule derived from basal lamina, promotes neurite outgrowth in a wide variety of neural cells including dorsal root ganglia (DRGs) and PC12 cells, a cell line derived from a rat pheo~ yLoma~ Kleinman et al., Annals NY Acad.
Sci. 580, pp. 302-10 (1990).
In development, the pathways followed by neural crest cells and the growth cones of pioneer neural cells contain several ECM constituents, including fibronectin, laminin, t~n~Cin, thL~ hospon~in and hyaluronic acid. Perris and Bronner-Fraser, Comments Dev. Neurobiol., 1, pp. ~1-83 (1989)-Thus, in one embodiment the agarose matrix is derivatized with neurite promoting agents and growth factors to specifically enhance neurite extension in , . . . . . . . . .. .. _ . . _ _ _ . .. ..

WO 96102186 219 4 4 9 3 r~llL~

agarose gels. It has been shown that the activity of the neurite promoting protein laminin is ~nh~n~ed after it is complexed with heparin sulfate proteoglycan which helps organize specific molecular interactions more favorable for neuritic outgrowth.
Integration of transplanted cells into host tissue results from growth of transplanted neurons, and from regeneration of axons from host neurons damaged during the transplantation, with the establishment of a functional interface, including graft-host interconnections and synaptic relationships. Woerly et al., Cell Trans~lantation, 2, pp. 229-39 (1993).
The 3-D agarose matrices of this invention may serve as a support for directed growth of axons. We prefer neural stem cells isolated according to Weiss et al., PCT/CA92/00283, most preferably human stem cells.
The physio-chemical environment of various cells and tissues in vitro may be tailored to evoke particular and specific responses from them. Specific ECM peptides may be important in ~et~r~;ning the degree of facilitation or permissivity to neurite outgrowth from neural cells. In particular, the nature of the peptide presented in 3-D can influence neurite extension. Further, cell types may be differently affected by a chosen peptide.
Neurite extension from PC12 cells in two-dimensions is ~nh~nced by the IKVAV (IleLysValAlaVal;
AA1l-AA15 of SEQ ID N0:3) fragment of LN (Tashiro et al., J. Biol. Chem., 264, pp. 16174-182 (1989)).
PC12 cells possess as 110 kDa cell surface receptor (Ribbey et al., Proc. Natl. Acad. Sci., 90, pp. 10150-53 (1993)) which has been postulated to be the binding site for the IRVAV (IleLysValAlaVal; AAll-AAls of SEQ ID
N0:3) sequence.

WO 9610n86 21~ 4 ~ 8 ~ S~

In a specific ~mho~i nt, agarose gels are derivatized with an IKVAV-containing sequence (IleLysValAlaVal; AAll-AA15 of SEQ ID N0:3) to promote neurite extension in PC12 cells.
The presence of nerve growth factor (NGF) may be required for neurite extension. See, e.g., Sephel et al., Biochem. BioPhvs. Res. Comm., 2, pp. 821-29 (1989). These growth factors may be incorporated into the channel membrane (United States Patent 5,011,486), or may be continuously provided within the channel by seeding the channel with cells that secrete the desired molecules, or a slowly released polymeric insert. See, e.g, United States Patents 5,156,844 and 5,106,627.
Such methods ~vel- - problems associated with short half lives of various of the growth factors, and problems with non-continuous or uncontrolled delivery of these factors.
In another specific ~mho~;r?nt, agarose derivatized with an RGD-containing sequence (ArgGlyAsp;
AA~-AA~ of SEQ ID N0:2), an CDPGYIGS~-containing sequence (CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1), IKVAV-containing sequence (IleLysValAlaVal; AAll-AA15 of SEQ ID N0:3) or a cocktail (PEPMIX) containing a mixture of all three sequences, was used to promote neurite extension in E9 chick dorsal root ganglia.
In another method of this invention, lamination of alternating non-permissive, permissive and non-permissive gel layers permits the creation of 3-D cell growth or migration "tracts" n Yi~- The agarose concentration for the non-permissive layer can be an agarose concentration greater than 1.25%, preferably 2.0% or greater.
In one ~mho~i~-nt, lamination of gel concentrations 2%:1%:2$, with the 1% gel layer carrying neural cells, e.g., dorsal root ganglia, can facilitate . ~ ~ = = = = = = = . = = = _ W096/02286 2 1 9 4 ~ 9 ~

i ~ .
. ZO --the creation of 3-D neural 'tracts'. Fabrication of the directed 3-D neural tracts of this invention can be achieved by physically casting neurite-extension permissive and non-permissive gels in a controlled manner. Such casting methods are known in the art.
The factors controlling nerve regeneration across a gap following transection injury are not fully understood. Regeneration of severed nerves does not normally include proliferation of nerve cells.
However, the injured nerve cell will extend neurites that growth distally and attempt to reenter the intact neurilemmal sheath of the distal portion of the severed nerve. Conventional techniques for repair involve aligning the severed ends of the fascicles. This manipulation and suturing stimulates growth and/or migration of fibroblasts and other scar-forming, connective tissue cells. The scar tissue prevents the regenerating axons in the proximal stump from reaching the distal stump to reestablish a nerve charge pathway.
Various nerve guidance rh~nn~l ~ have been developed in attempts to overcome these problems. See, e.g. United States Patents 5,030,225 and 5,092,871.
one critical event in regeneration across a gap in smooth-walled silicone elastomer tubes is the formation of a fibrin cable bridge which serves as a scaffold for migrating cells and elongating axons. Schwann cells, axons, endothelial cells and fibroblasts subsequently enter the gap region and orient into regeneration units, blood vessels and epineurial and perineurial tissue, respectively. Aebisher et al., Brian Research.
531, pp. 211-18 (1990).
The agarose hydrogel compositions of this invention may be useful in nerve guidance channels.
Such nerve guidance rh~nn~l.q are well known in the art.
Synthetic guidance channels have been used as inert 2~9~49~

conduits providing axonal guidance, maintaining growth factors, and preventing scar tissue invasion.
Permselective rh~nnol c with a molecular weight cut-off - of 50,000 daltons allowed regeneration of nerves in a mouse sciatic nerve model. The regenerated nerves were characterized by fine epineurium and high numbers of myelinated axons. Aoh; crhor et al., "The Use Of A
Semi-Permeable Tube As A Guidance Channel For A
Transected Rabbit Optic Nerve", In Gash & Sladek ~Eds]
Proqress in Brain Research, 78, pp. 599-603 (1988).
Permselective rh~nnelc may support regeneration by allowing inward passage of nutrients and growth or trophic factors from the external host environment, while preventing the inward migration of scar-forming cells. Cells participating in the wound healing phPn ~ are known to release various peptide growth factors. Several of these factors have molecular weights in the range 10-40,000 daltons. For example, activated macrophages secrete numerous growth factors, including NGF, bFGF, and apolipoprotein E.
Schwann cells distal to the nerve injury express low affinity NGF receptors, as well as apolipoprotein B and E receptors. Binding of apolipoprotein E to these receptors may enhance lipid uptake which can eventually be used in remyelination.
APhicrhpr et al., Brain Reco~rch~ 454, pp. 179-87 (1988). Appropriate choice of the molecular weight cut-off for the permselective rh~rnPlq will allow retention of laminin (a high molecular weight glycoprotein) within the nerve guidance channel.
Similarly, blood vessels located in the proximal nerve stump may supply high molecular weight serum molecules such as fibronectin or glycoproteins that have supported neuronal survival and neurite extension W096f02286 2 1 9 4 4 9 3 :~ -.22 -m vitro. Aebischer et al., Brain Research, 454, pp. 179-87 (1988).
The nerve guidance channels of the present invention include an implantable, biocompatible tubular p~~ ~~lective membrane having openings to receive the severed nerve. The lumen of the membrane preferably has a diameter ranging from about 0.5 mm to about 2.0 cm, to permit the nerve to regenerate through it.
The thickness of the membrane may range from about 0.05 to about 1.0 mm. In some embodiments the membrane has a molecular weight cut-off of about 100,000 daltons or less. The membrane is preferably impermeable to fibroblasts and other scar-forming conn~ct;ve tissue cells. Additionally, the membrane may be composed of a biodegradable material. An agarose matrix is disposed in the lumen of the nerve guidance channel. The agarose concentration should range between 0.5 to 1.25%, preferably 1.0%. The average gel pore radius can vary between 120 to 290 nm, and is most preferably approximately 150 nm.
The optimal conc~llLL~tion of agarose gel for use as a regeneration matrix will vary according to the intended use of the matrix. The optimal concentration for in Yi~Q use may not be optimal for the n vivo milieu. Neurite outgrowth in agarose gels is strongly ~p~n~nt upon the pore size of agarose gels.
Syneresis at the channel mid-point could alter the pore size of agarose gels enough to inhibit regeneration and therefore result in the absence of nerve cable in the mid-portion of the regenerated nerve bundle. It is important to account and if possible, correct for syneresis of the gel at channel mid-point. This may be ~V~l~ - by two strategies. One, the use of more dilute agarose gels to fill the channels may 35 a~ te syneresis in the middle and still retain ~ W096~2286 2 ~ ~ ~ 4 g 3 the pore size of gel at the channel midpoint to ranges permissible for neurite extension. Second, the use of a rough inner membrane of the channel may serve to prevent the fibroblast induced syneresis of the gel inside the guidance channel (Aebischer et al., Brain Research, 531, pp. 21-18 tl990)).
In one method of repairing a severed nerve according to this invention, the cut ends of the nerve are placed in proximity with each other within the lumen of the tubular guidance channel. The cut ends of the nerve are gently drawn into the channel by manual nip~ Ation or suction. The nerve ends may be secured in position without undue trauma by sutures, or using a biocompatible adhesive, e.g., fibrin glue, or by frictional engagement with the channel.
In addition to the agarose matrices of the present invention, the lumen of the channel may be "seeded" with a substance that protects, ~IUL LUL~S, and/or ~hAnc~c nerve growth therethrough. Useful substances include biologically active factors, such as nerve growth factors, brain derived growth factor, basic fibroblast growth factor, acidic fibroblast growth factor, or active fragments thereof.
Alternatively, the lumen may be seeded with nerve-associated glial cells, such as Schwann cells. Thecegrowth factor cells and other nutrients may be provided within the nerve guidance channel as described suPra.
The bioartificial ECMs of this invention may also carry one or more of the several cell adhesion molecules that have been identified to play an important role in cell migration and neurite extension in the developing nervous system, including N-CAM, Ng-CAM (Crossin et al., Proc. Natl. Acad. Sci., 82, pp. 6942-46; Daniloff et al., J. Neurosci., 6, pp. 739-58 (1986); t~nACCi~ (Wehrle et al., Develo~ment, 1990, W096/02286 ~ P~~
944g3 . j pp. 401-15 (1990) and Ll (Nieke et al., Differentiation, 30, pp. 141-51 (1985).
Other useful factors include cAMP, or analogs thereof, including 8-bromo cA~P or chlorophenythio cAMP. See, e.g., United States Patents 5,030,225 and 5,011,486.
The nerve guidance rhAnn~lc of this invention may additionally be seeded with Schwann cells. Schwann cells resident in the peripheral nerve trunk play a crucial role in the regenerative process. Schwann cells seeded in permselective synthetic guidance rhi~llllPl fi support extensive peripheral nerve regeneration. Schwann cells secrete laminin, which p~Sfi~CS~c neurite-promoting activity n vitro. See, e.g., Aebischer et al., Brain Research, 454, pp. 179-87 (1988). The Schwann cells are preferably longitudinally oriented along the guidance channel.
This can be achieved by thermal manipulation of the agarose gel to orient the pores longitudinally, using ZO methods well known in the art.
Insulin-like growth factor 1 (IGF-1) may also be useful in increasing the rate of regeneration of transected peripheral nerves and to decrease the persistence of permanent nerve function deficiency.
See, e.g., United States Patent 5,068,224.
Preferably the permselective membrane is fabricated to be impermeable to some of these substances so that they are retained in the proximity of the regenerating nerve ends. See, e.g., Aebischer, United States Patent 5,011,486.
Briefly, various polymers and polymer blends can be used to manufacture the nerve guidance channel.
Polymeric membranes forming the nerve guidance channel may include polyacrylates (including acrylic copolymers), polyvinylidenes, polyvinyl chloride ~ WO 96102286 ~ 4 4 9 3 ~ 51~,~8~

copolymers, polyurethanes, polystyrenes, polyamides, cellulose acetates, cellulose nitrates, polysulfones, polyphosphazenes, polyacrylonitriles, poly(acrylonitrile/covinyl chloride), as well as derivatives, coplymers and mixtures thereof.
The membranes used in the nerve guidance rhAnn~l~ of this invention may be formed by any suitable method known in the art. One such method involves coextrusion of a polymeric casting solution and a coagulant as described in Dionne, WO 92/19195 and United States patents 5,158,881, 5,283,187 and 5,284,761, incorporated herein by reference.
The jacket may have a single skin (Type 1, 2), or a double skin (Type 4). A single-skinned hollow fiber may be produced by quPnehin7 only one of the surfaces of the polymer solution as it is co-extruded.
A double-skinned hollow fiber may be produced by qll~nrhing both surfaces o~ the polymer solution as it is co-extruded. Typically, a greater percentage of the outer surface of Type l hollow fibers is occupied by macru~L~s compared to Type 4 hollow fibers. Type 2 hollow fibers are intermediate.
The jacket of the nerve guidance channel will have a pore size that determines the nominal molecular weight cut off (nMWCO) of the permselective membrane.
Molecules larger than the nMWCO are physically impeded from traversing the membrane. Nominal molecular weight cut off is defined as 90% rejection under convective conditions. Typically the MWCO ranges between 50 and 200 kD, preferably between 50 and 100 kD
A preferred nerve guidance channel according to this invention for promoting regeneration of peripheral nerves across large gaps, includes an agarose matrix optimized in the regeneration environment to suit the re-growth of a particular _ _ _ _ . .. .. _ .. .

W096/02286 2 1 9 4 ~ 9 3 1 Cl/. s LO~

.. . .
nerve, the presence of Schwann cells seeded in the lumen of the channel, and the local release of growth factors from the wall of the guidance channel.
In one ~rhoA;r nt, agarose hydrogels are used as a carrier to present the laminin derived oligopeptide CDPGYIGSR (CysAspProGlyTyrIleGlySerArg;
SEQ ID NO:1) to the site of nerve injury in an attempt to enhance nerve regeneration. Dorsal root ganglia have been shown to be responsive to CDPGYIGSR
(CysAspProGly TyrIleGlySerArg; SEQ ID N0:1) m vitro and show the greatest enhanced neuritic spread and neurite outgrowth compared to other fragments derived from laminin.
Compared to the ventral roots, transected dorsal roots have a limited regeneration through polymeric guidance rh~nn~l~ across a nerve gap of 4 mm in adult rats after 4 weeks. McCormack et al., J. Com~. Neurol. 313, pp. 449-56 (1991). Rat hind limb sural nerves have been shown to contain mainly sensory nerves with only 5% to 10% motor fibers Peyronnard et al., Muscle and Nerve, 5, pp. 654-60 (1982). Dorsal root and sural nerve transection enables comparison of regeneration between a sensory nerve cable close to the central nervous system, i.e., dorsal root, and one that is more peripheral, i.e., the sural nerve.
In order that this invention may be better understood, the following examples are set forth.
These examples are for purposes of illustration only, and are not to be construed as limiting the scope of this invention in any way.

W096/02286 2~ g 4~g3 P~

Exammles E le 1 - Characterization of A~arose Hy~ro~el _ Matrices E14 striatal cell assay Striata were removed from 14-day-old rat embryos and mechanically dissociated with a fire-narrowed Pasteur pipette in serum-free medium.
Different concentrations of agarose gels in the range of 0.5% to 5.0% were made in phosphate buffered saline pH 7.4. Gel solutions were sterilized by passing them through sterile 0.2 micron filters. Isolated E14 striatal cells were mixed into the gel solutions at room temperature in 1 ml syringes, each containing 300 ~1 of appropriate agarose gel concentration. The cell-gel solution mixture was then decanted into 48 wellCostar tissue culture dishes. The dishes were cooled to 4~C for the cell-gel solution mixture to gel, s--qp~n~ i ng the striatal cells in 3-D. One ml of a 1:1 mixture of DMEM a*d F12 nutrient (Gibco) supplemented with 5% fetal calf serum, glucose (33 ,M), glutamine t2mM), sodium bicarbonate (3 mM), HEPES buffer (5 mM, pH 7.4), insulin (25 ~g/ml), transferrin (100 ~g/ml), putrescine (60 ~g/ml), progesterone (20 nM) and sodium selenite 30 nM) (all from Sigma) was added to the top of the gels. The gels were cultured in an incubator at 37~C in 95% air, 5% C02 and 100% humidity. Striatal cells were also 5ncp~n~d in 100~ MatrigelO at 4~C and quickly decanted into 48 well Costar dishes and cultured in the manner describes above.
The percent striatal cells ~Yp~n~inq neurites of every 500 cells suspended in 3-D was measured for the agarose gel range of 0.5% to 5.0% (wt/vol) at 24, 48 and 72 hours in culture. Neurite extension was observed under light microscopy using a Zeiss Axiovert NC100 phase inversion microscope. All neurites whose W096l02286 2 1 9 A 4 9 ~ s. ~. ~

length was greater than twice the striatal cell body diameter were counted.
E14 striatal cells extended neurites in 3-D
in 1% agarose gels. Neurite extension from E14 striatal cells in 1% agarose gels was comparable to neurite extension in 100% Matrigel~ after 72 hours in culture. E14 striatal cells extended neurites in the 0.5% to 1.25% gel range but did not extend neurites above a threshold concentration of 1.25% (wt/vol).

Chick eorsal root ganglion assay Dorsal root ganglia were dissected from E9 chick embryos by a standard protocol. Chick embryos were immobilized in a prone position and a 3 mm long incision made on either side of the spine exposed DRGs for explanation. The DRGs were added to a 300 ~1 solution of 1% agarose in a lml syringe at room temperature, mixed gently and decanted into custom-built 9x9mm cube shaped glass culture dishes. The 9x9 mm dishes were then placed at 40C for agarose to gel, trapping DRGs in 3-D. The cubic glass dish enables v;R~1;7ation of the X-Z axis, which is the plane perpendicular to the bottom of the culture dish. Three hundred microliters of 1% Ag-Plain gel solution was drawn into a 1 ml syringe, and the DRGs added to the gel solution with a micropipette. The ganglion-gel solution mixture was then decanted into the 9x9 dishes and cooled at 4~C for 5 min, trapping the DRGs in the gel. Each well had two DRGs sncp~n~ed int it. One ml of DMEM/F12 medium (Gibco) containing 10 ng/ml 2.5s nerve growth factor (Sigma), glucose (0.3%), penicillin-streptomycin (1%), L-glutamine (200 mM), KCI
(1.5mM), insulin (0.08 mg/ml), transferring (10 mg/ml), putrescine (6mM), and 5% fetal calf serum was added to the top of the gels. The cultures were maintained in WO 96/02286 ~ L. ~I~ ,.co~
219~3 an incubator at 37~C with 100% humidification, 95% air ~ and 5% C02. The cubic glass dish was flipped on its side after 6 days in culture, exposing the X-Z axis for analysis with light microscopy.
For neurite extension analysis along the X-Y
axis, which is the plane parallel to the bottom of the culture dish, DRGs were s~cp~n~d in plain agarose, agarose-GRGDSP (GlyArgGlyAspSerPro; SEQ ID N0:2), agarose-CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ ID
N0:1), agarose-x-IKVAV(IleLysValAlaVal; AAll-AAls of SEQ
ID N0:3)-x, agarose-PEPMIX and agarose-GGGGG
(GlyGlyGlyGlyGly; SEQ ID N0:4) gels in standard 48 well Costar tissue culture dishes in the manner described above for the cubic glass culture dishes. At least 6 ganglia were analyzed for each type of agarose gel.
The final concentration of the cell-gel solution mixture was 0.83% (wt/vol) and the total cell-gel volume in each culture well was 300 microliters.
Chick DRGs extended neurites in 1~ agarose gels in both the X-Y and X-Z planes when cultured in the custom designed 9x9 mm glass cubic dishes after 6 days in the presence of NGF. DRGs extended long and tortuous neurites along the X-Y axis and the X-Z axis ~ LL~ting the 3-D nature of neurite extension in agarose gels.

Gel Characterization a. Hydraulic p~ --hility: Gel blocks of different concentrations, each of thickness 0.5 cm and radius 1 cm, were mounted on a custom-built water column. Each block was subjected to a known hydraulic pres6ure, typically a 100 cm high H20 column yielding approximately 24525 dynes/cm2. The hydraulic permeability per unit time for a given hydraulic ples~uLe was measured for the various gel W096/02286 '~ r~
~19~93 ~ concentrations. The average pore radius of the gel concentration range 0.5% to 5.0% was calculated as described by Refojo et al., J.A~l.PolY.Sci., 9, pp. 3417-26 (1965~ using the hydraulic permeability.
The average pore radius, calculated from the hydraulic permeability measurements of the various agarose gels, decreased exponentially as the gel concentration increased (Figure 1). E14 striatal cells did not extend neurites beyond a threshold agarose gel pore radius of 150 nm. The slope of the curve depicting pore radius was steep between gel aon~ LL~tions of 1% and 2% indicating a strong depPnd~nre of pore size on gel concentration.
k. ~c~nnin7 Electron miuLosc~yy (SEM~:
Agarose gels in the range 0.5% to 2.0% were freeze-dried, mounted on aluminum stubs, coated with gold and analyzed under a Joel 35M scanning electron microscope.
R~Les~,lLative sections of the sr~nn;n~ electron micrographs were selected for evaluating the morphology and size of the pores.
Scanning electron micrographs of different concentrations of agarose gels revealed an open-cell morphology.
c. Electron miu~osc~y (E8EM): Agarose gels of the concentration range 0.5% to 2.5% were analyzed with an environmental scanning electron micrograph (Electroscan ESEM, type E3) under partially hydrated states to qualitatively asses gel pore morphology.
A decline in gel cavity radius was noted with increasing gel concentration. ~owever, the nature and quality of images obtained with the ESEM allowed only qualitative conclusions on gel pore size to be drawn with confidence.
d. Gel electrophoresis: The electrophoretic mobility of insulin (Mw 5,700), bovine serum albumin W096/02286 2 1 9 ~ ~ 9 3 ~ ? ~

(Mw. 66,000; radius 140 Angstroms) and bovine thyroglobulin (Mw. 669,000) in 1%r 2% and 4% agarose gels was measured under a constant electrophoretic - voltage gradient. Twenty ml of the appropriate agarose gel concentration was poured into a DANAPHOR model 100 mini gel electrophoresis apparatus (Tectate S.S, Switzerland) with platinum electrodes. The proteins insulin, albumin and thyroglobulin were then sub~ected to a constant electrophoretic voltage gradient of 1 to 12V. The protein electrophoretic mobility was measured in the 1%, 2% and 4% agarose gels by measuring distance traveled per unit time. The relative electrophoretic velocity was then calculated after taking into account the isoelectric points of the different proteins, the voltage employed and the time of ~x~o~uLe to enable electrophoretic mobility comparisons of insulin, albumin thyroglobulin in the agarose gels.
The relative electrophoretic mobility of the globular proteins insulin, albumin and thyroglobulin, fell with increasing gel concentration. The electrophoretic mobility of insulin and albumin decreased by relatively small percentage in 2% agarose gels compared to 1% gels i.e., by 5.7% and 2.9%
respectively. In contrast, the relative electrophoretic mobility was attenuated by 33.3% in 2%
agarose gels relative to that in 1% agarose gels for the large molecular weight globular protein, bovine thyroglobulin.

L~inated Gels A 3 mm thick, cell-free layer of non-permissive 2% agarose gel solution, a l mm layer of permissive 1% gel solution with chick DRGs mixed in it, and an additional 3 mm, cell-free layer of non-permissive 2% agarose solution were serially cooled and W096/02286 2 1 9 4 ~ ~ 3 .. . .

gelled in a custom designed sx9 mm cubic glass dishes.
The dishes were then turned on their side exposing the X-Z axis and analyzed under light microscopy after 6 days in culture. The gel interfaces were ~Y~m;nPd for neurite cross-over from one gel layer to the other.
Chick DRGs Encr~n~ed in the permissive 1%
agarose gel layer extended neurites only in the 1% gel and did not cross-over the 1%:2% gel interface. In comparison, many neurites were able to cross-over a control gel interface of 1%:1~ agarose gel. By experimental design, all the neurites encountering the interfaces were extending in the X-Z axis of the gel, perpendicular to the bottom of the culture dish.

~Y~mnle 2 - A Bigartificial ECM of Oliqo~eotide-derivatized Aqarose Preparation of agarose gels One percent (wt/vol) hydroxyethylated agarose (SeaPrepl, FMC Corp. Rockland, Maine) gels were prepared by dissolving aqarose in phosphate buffered saline (PBS) at pH 7.4. The gel solutions were passed through a 0.2 micron filter for sterilization. Gel solutions were then placed at 4~C, allowed to gel, and stored at 4~C until they were derivatized with peptides.

~ ~ tion of laminin oligopeptideq Agarose gels were derivatized with 1,1 carbonyldiimidazole (CDI) (Sigma) using a modified version of the protocol described by ~earn, Methods ~n7vmol., 135, pp. 102-17 (1987). See Figure 2 for schematic. Three to four ml gel blocks of i% agarose were dehydrated by repeated washes in acetone followed by acetone which was dried under 4 Angstrom molecular sieves (Sigma). A 150mg/25ml CDI solution prepared in W096/02286 ~ 4~3 dry acetone was added to the acetone washed agarose gels (5ml/3g gel block). The activation reaction was allowed to proceed for 9 min with gentle agitation.
Gels were then washed five times with dry acetone for 6 min per wash to remove unbound CDI.
CDI activated gels were then exposed to various oligopeptides dissolved in 100 mM sodium bicarbonate buffer solution at pH 8.5 at a concentration of 0.6 mg/ml. Peptide coupling reaction was allowed to proceed for 36 hr under gentle agitation.
The gels were then washed thoroughly with PBS
for 48 hr, further quenched in sodium bicarbonate for 2 hr at room temperature, lyophilized and re-dissolved to the desired gel ~oncenL,~tion of 1.0~.
The peptides used were GRGDSP
tGlyArgGlyAspSerPro; SEQ ID N0:2) (Telios pharmaceuticals, San Diego CA), CDPGYIGSR
tCysAspProGlyTyrIleGlySerArg; SEQ ID N0:1), the 19-mer sequence CSRARXQAASIRVAVSADR (CysSerArg AlaArgLysGlnA 1 A A 1 A C~rI leLysValAlaValSerAlaAspArg; SEQ
ID N0:3), an x-IKVAV-x containing sequence (x-IleLysValAlaVal-x; AAll-AA15 of SEQ ID N0:3) (Anawa, Wagen, Switzerland) and as a control, GGGGG
(GlyGlyGlyGlyGly; SEQ ID N0:4) (Sigma). A cocktail of the three aforementioned peptides (PEPMIX) was also immobilized to the hydrogel backbone at a concentration of 2 mg each in a total of 5 ml buffer solution.
The 1'1 carbonyl~;;m;~A7ole coupling reaction used for immobilizing peptides to the agarose gels was verified by binding radiolabelled 14C glycine as a model amino compound for the various peptides. Gels which were not activated with CDI, but exposed to 14C
glycine were used as controls. Beta counts from CDI
activated and CDI deficient gels were counted with a WO 96/02286 2 1 9 4 ~ 9 ~ 1 l/U~
,''' ~ ,~ 34 -counter (LKB Wallac, 1217 RackBeta liquid scintillation counter) after dialyzing for 12 days.
CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ
ID NO:1) was labelled with 125I using lactoperoxydase (Sigma). Ten ~il of CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID NO:1) solution in 0.4 M sodium acetate solution (5 ~g/10~1 of sodium acetate), 1 millicurie of 125I (Amersham Radio Chemicals) and 10 ~1 of hydrogen peroxide (~2~2; 1 in 20,000 parts). The reaction was allowed to proceed for 1 min and stopped with 500 ~1 of 0.1 M sodium acetate solution.
- Radiolabelled CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID NO:l) was eluted with 20% to 50% methanol in an octodesasilicic acid (ODS) gel column (Shandon Scientific Ltd., Cheshire England~. 125I CDPGYIGSR (CysAspProGlyTyrIleGlySerArg;
SEQ ID NO:l) was coupled to agarose gels in the manner described above. Gamma counts were analyzed with a Packard autoscintillation spectrometer (5416) after 5 days of washing to remove unbound peptide.
Beta counts of 14c glycine bound to CDI
derivatized agarose revealed that up to 37 ~g of glycine was retained per gm of gel after 12 days of dialysis. CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ
ID NO:1) was successfully radiola~elled with 125I and the peak elution is ODS gels was the 40% methanol. In the presence of CDI, 2.39 times more 125I labeled CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ ID NO:1) was retained in agarose gels compared to gels without CDI after 5 days of dialysis of the gel. The short half-life period of l25I prevented further washing even though the gamma counts in the CDI deficient gel were failing more rapidly with each successive wash compared to the counts in CDI activated agarose gel.

~ W096/02286 2 ~ ~ ~ 4 ~ 3 Gel char~cteriz~tion Gel porosity of underivatized agarose gels and glycine coupled agarose was determined as described in Example l. The average pore radius of the gels were determined to be 310 nm for a 0.5~ underivatized agarose gel and 360 nm for a 0.5~ glycine coupled agarose gel using the water column for hydraulic permeability measurements.

Dor~al root ganglion as~ay DRGs were dissected from E9 chick embryos by a standard protocol, as described in Example 1.
Neurite extension was analyzed qualitatively along the X-Y axis using a Zeiss axiovert MClO0 TV
light microscope at days 2, 4 and 6. Cell viability of both cell types was assessed by a fluorescein diacetate tFDA) assay at day 6. For the DRG study, the ganglionic cell body area (GCBA), and the total ganglionic spread area (TGSA) defined as the maximum area covered by the ganglion and its neurites, were measured in the X-Y plane using an NIH Image 1.47 software package. The ratio of TGSA/GCBA, defined as the total neuritic spread of the ganglia, was calculated. The length of five of the longest neurites extended by the DRGs was also measured to assess neurite extension.
Agarose hydrogels supported neurite outgrowth from DRGs in both X-Y and X-Z planes, demonstrating the 3-D character of neurite outgrowth in agarose gels.
Fluorescein diacetate assay showed viable DRG neurons after 6 days in culture in all agarose gels used.
DRG neurons extended neurites in all of the agarose gels when examined in the X-Y plane in 48 well W096/02286 ~ P~~
2194~93 Costar dishes including Ag-Plain and Ag-CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1).
The total ganglionic spread area/ganglionic cell body area ratio (TGSA/GCBA) was calculated at days 2, 4 and 65 to account for the variance in the size of the dorsal root ganglia after dissection and as a measure of the total neuritic spread in the gels (Figure 3). Compared to AgPlain gels, Ag-PEPMIX gels showed significantly greater neuritic spread at all measured time points (p<0.05) while CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg;~SEQ ID N0:1) had significantly grater neuritic spread only at day 6 (p<0.05). In contrast, IKVAV-derivatized (IleLysValAlaVal; AA11-AA15 of SEQ ID N0:3) gels had significantly lesser neuritic spread at all measure time points while GRGDSP (GlyArgGlyAspSerPro; SEQ ID
N0:2) had significantly lower neuritic spread only at days 2 and 4 (p<0.05), compared to AgPlain gels at all measured time points.
CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ
ID N0:1) and PEPMIX derivatized agarose gels supported significantly longer neurites than underivatized agarose gels (p<0.05) at day 6 (Figure 4). In contrast, IKVAV-derivatized (IleLysValAlaVal; AA11-AA15 of SEQ ID N0:3) agarose gels inhibited neurite outgrowth at days 2, 4 and 6 (p<0.05). Ag-GGGGG
(GlyGlyGlyGlyGly; SEQ ID N0:4) gels had a significantly lower (p<0.05) neurite length compared to Ag-Plain at day 2 but there was no statistical difference in neurite length between the two gels at days 4 and 6.
In all the agarose gels, neurites extended three dimensionally including the X-Z plane. The neurites were long and tortuous, extending up to 1600 microns at day 6 in CDPGYIGSR-derivatized ~CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) gels.

~ W096/02286 2 1 9 ~ ~ 9 3 PC12 cell assay PC12 cells (American Type Culture Collection, Rockville, Marylandj were grown in Gibco's ~PMI 1640 with 10% fetal calf serum, 5% horse serum, L-glutamine t200 mM) and 1% penicillin-streptomycin. They were primed at the tenth passage with 10 ng/ml 2.5s nerve growth factor (NGF) for 48 hr prior to use. Primed PCl2 cells were then mixed in the various agarose gel solutions at a density of 50,000 cells per ml using a method similar to the one described above for DRGs.
The cell-gel solution mixtures were poured into 48 well Costar tissue culture dishes and allowed to gel by cooling 4~C. One ml of PCl2 medium was added to the tope of the gels along with 10 ng/ml of NGF. The cultures were placed in an incubator at 37OC with 100%
humidification, 93~ air and 7% C02.
The percentage of PCl2 cells extending neurites in the various agarose gels was ACC~CC~ by selecting optical cylindrical sections of the gels for analysis at a magnification of 200x under light microscopy. Optical cylindrical sections were chosen by serially moving the microscope visual field from the center of the dish to the side along parallel paths.
At least nine hundred PCl2 cells were ~Y~mined for neurite extension in each well and at least 6 wells of each type of agarose gel were analyzed. The inclusion criterion for a positive count was a neurite longer than on PCl2 cell body diameter. Two sided Student t-test was employed to determine statistical significance with p<0.05 considered to be significant.
PC 12 cells were viable as evidenced by an FDA assay in all gels except Ag-GGGGG (GlyGlyGlyGlyGly;
SEQ ID NO:4). PCl2 cells also extended neurites in all gels after 6 days in culture except in Ag-GGGGG

-W096/02286 . ~ 5 ~
2~94~93 (GlyGlyGlyGlyGly; SEQ ID N0:4) gels. However, the percent PC12 cells that extended neurites depended upon the type of gel used. At all measured time points, the laminin oligopeptide derivatized agarose gels supported significantly greater percent neurite extension (p<0.05) than underivatized Ag-Plain gel. Neuritic extension in Ag-x-IKVAV(IleLysValAlaVal; AA1~-AA~5 of SEQ ID N0:3)-x gels was significantly higher (p<0.05) compared to the Ag-GRGDSP (GlyArgGlyAspSerPro; SEQ ID
N0:2), Ag-CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ
ID NO:l), Ag-PEPMIX and underivatized agarose gels at days 4 and 6 (Figure 5).
In the absence of NGF, no neurite extension was observed in any of the agarose gels. No measurable difference in the neurite length was observed between the Ag-plain and the various derivatized agarose gels (data not shown). The overall percent of PCl2 cells extending neurites in the various derivatized agarose gels, IKVAV-derivatized (IleLysValAlaVal; AA11-AA75 of SEQ ID N0:3) gels including, was lower than the percent cells extending neurites in 100% Matrigelc or l.2 mg/ml Vitrogen~ gels (36.5% and 32.8~ respectively at 4 days).
r le 3 The effect of derivatized agarose gels on the regeneration of transected rat spinal dorsal roots was evaluated by using 6 mm long polymer guidance rhAnn~1~
filled with CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ
ID NO:l) - agarose to bridge a 4mm gap in a transected dorsal root model. After 4 weeks, significantly greater numbers of myelinated axons were observed in the rh~nn~l ~ filled with CDPGYIGSR (CysAspProGly TyrIleGlySerArg; SEQ ID NO:l) - agarose gels compared to rh~nn~l~ filled with underivatized agarose gels.

~ WO 96/02286 ~ g 3 rc.,.J~

r ~ 39 ~

Gui*-r-~ c~-nn~l~
Guidance chAnnP7S were fabricated from acrylonitrile-vinylchloride (PAN/PVC~ copolymers by wet-jet wet spinning. Cabasso, I., In EncYclo~edia of Chemical TechnoloqY, 12, pp. 492-517 (1978); Aebischer et al., Biomaterials, 12, pp. 50-56 (1991). The channel consisted of a smooth imler and outer skin with a molecular weight cut-off 50,000 Da, with an open trabecular network in between, which provided the structural support for the channel. chAnnPlc of internal diameter 0.8 mm and 0.5 mm were fabricated for the spinal root and sural nerve model respectively.

CDPGYIG8R derivatized agarose gels One percent (wt/vol) agarose gels were derivatized with LN oligopeptide CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID NO:1) as described in Example 2. PAN/PVC guidance rh~nnPl~ were sterilized by storing in 70~ ethanol overnight.
G~ Anre rhAnnPl~ were filled with CDPGYIGSR
(CysAspProGlyTyrIle GlySerArg; SEQ ID NO:1) derivatized and underivatized agarose gel solutions and the ends of the channel were sealed with heat to prevent leakage of gel solution. The rhAnn~l~ were then cooled to 4~C to allow agarose solutions to gel. After agarose solutions "gelled" inside the channels they were cut to a standard length of 6 mm and 10 mm for the dorsal root and sural nerve implants respectively.

Animal model and guidance channel implantation Adult male albino rats (Wistar) weighing 180 30 to 220 gm were anesthetized by an intraperitoneal injection of pentobarbital (60 mg/kg). The dorsal operative site was shaved and swabbed with an iodophore . _ . _ . _ . . . . _ _ _ _ _ _ ~ . . .

W096/02286 ~ 5 ~
2i~4~g3 ' ' ' ~

i, tButadiene). A 5 mm dorsal midline incision was made using the iliac crests as landmarks. Retraction of paraspinous muscles exposed L2-L6 vertebrae. Bilateral laminectomies were performed on L2 to L5 to expose the spinal cord. The spinal roots were exposed by a midline incision on the dura mater. Using a blunt nerve hook the dorsal root exiting the L4 vertebra was identified and a 2 mm section removed. six millimeter long guidance rh~nn~l q carrying underivatized agarose and CDPGYIGSR-derivatized (CysAspProGlyTyrIleGlySerArg;
SEQ ID N0:1) agarose were used to bridge the 2 ends of the nerve using a 10-0 monofilament nylon suture (Ethicon) (see Figure 6 for schematic). Five rats received ~h~nn~l c filled with underivatized agarose and six animals received ~h~nn~l~ filled with CDPGYIGSR-derivatized (CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) agarose.
For the sural nerve model, the hind limb operative site was shaved and cleaned with iodophore.
"L" shaped incisions were made on the left hind limbs of 180-220 g albino rats (Wistar) along and dorsal to the femur and continuing past the knee. The gluteus maximus muscle was retracted and the sciatic nerve was exposed. The sural branch of the sciatic nerve was identified, followed down beneath the knee joint, and a 2 mm long piece of the nerve was transected. The ends of the nerve were then bridged with guidance channels which were filled with either saline or underivatized agarose or CDPGYIGSR-derivatized (CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) agarose.
Five animals received saline filled ~h~nn~l~, five received agarose plain ~h~nn~l c and four received CDPGYIGSR(CysAspProGly TyrIleGlySerArg; SEQ ID N0:1)-agarose filled ~h~nn~l c. All animals were housed in an W096/02286 ~ ~ 4 4 ~

controlled environment with 12 hour on-off light cycles. They received food and water ad libitum.

Implnnt retrieval and evaluation Four weeks post-implantation, the animals were deeply anesthetized with an intra-peritoneal injection of sodium pentobarbital and transcardially perfused with 200 ml of heparinized physiologic saline followed by 250 ml of a cold 4% paraformaldehyde 2.5%
gluteraldehyde solution in phosphate buffered saline at pH 7.4. The operative site was reopened, and the guidance channel retrieved. The specimens were post-fixed, dehydrated and embedded in glycomethacrylate.
The cable cross-sectional area, the number of myelinated axons at 1.5 mm, 2 mm and 3.5 mm of the dorsal root channel were analyzed with NIH software 1.47 interfaced with a Zeiss Axiovert MClOO microscope.
The proximal nerve stump was defined to be at the 0 mm point and the distal nerve stump at the 4 mm point of the 4 mm nerve gap in dorsal roots. For the sural nerve implants, the cable cross-sectional area and the number of myelinated axons at 2 mm point along the channel was evaluated on 6 micron semi-thin sections.
All sections were stained with osmium tetraoxide and cresyl violet.

Dorsal root regeneration Semi-thin cross-sections along the length of the guidance channel showed that myelinated axons were present all along the 4 mm nerve gap. Histological sections of guidance channels filled with agarose gels carrying regenerated dorsal roots showed doughnut shaped, centrally located nerve cables. Tissue reaction to the PAN/PVC polymer consisted of multi-nucleate giant cell and connective tissue infiltration.

W096/02286 2 1 9 4 4 9 3 i~ P~ 5 ,~

Neovascularisation was evident in the midst of regenerated nervous tissue along with Schwann cell infiltration. Light micrographs of regenerating dorsal root cables at 4 weeks post-implantation at the mid-point of guidance channels showed comparatively morenervous tissue in ~h~nnPlc containing CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) gels relative to channels with underivatized agarose. At the mid-point of the 4 mm nerve gap, the channel filled with AgCDPGYIGSR (CysAspProGly TyrIleGlySerArg; SEQ ID
N0:1) had a significantly greater (p < 0.05) number of myelinated axons compared to the rhAnnPlc with agarose plain gels (see Figure 7). The number of myelinated axons at the midpoint in the agarose plain filled t~h~nnPlc were comparable to those in saline filled rh InnPl.c described by McCormack et al., J.Com~.
NPnrol.~ 313, pp. 449-56 (1991). CDPGYIGSR-derivatized (CysAspProGly TyrIleGlySerArg; SEQ ID N0:1) agarose gels had a significantly higher density (p < 0.05) of myelinated axons at 0.5 mm and 2.0 mm along the channel at 4 weeks postimplantation (Figure 8). The density of myelinated axons is defined as the number of myelinated axons per 105 square microns of cable area.

Qural nerve regeneration All of the 10 mm long guidance t~h~nnP~c implanted to bridge transected sural nerves were kinked due to flexion at the rats' knee-joint. Histological evaluation of nerves proximal to the kink showed regenerated cables located at the center of the channel with myelinated axons. All cables present in the channel distal to the kink contained a fibrotic cable but no myelinated axons. Almost all of the kinks occurred between 2-4 mm into the nerve gap. Therefore only the 2 mm point was analyzed for myelinated axons _ . _ _ _ _ _ . _ _ _ _ _ _ _ _ ~

219~4g3 in this study. Light micrographs of regenerating sural nerves, 4 weeks post-implantation at the 2.0 mm point in polymer guidance rhAnnPls filled Ag-CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) showed relatively higher numbers of nerve fascicles and neovascularization than in the other guidance rhAnn~ls.
At 2 mm into the 8 mm nerve gap, guidance ~hAnnPl5 filled with AgCDPGYIGSR(CysAspPro GlyTyrIleGlySerArg;
SEQ ID N0:1) gels had a significantly greater number (p < 0.05) of myelinated axons compared to either the saline filled rhAnnPls or agarose plain filled rhAnnels. See Figure 9. At this point, the density of myelinated axons in the CDPGYIGSR-derivatized (CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) agarose rhAnnPl~ was also significantly greater (p < 0.05) than the density of axons in the agarose-plain and saline-filled rhAnnPls (Figure 10). When the number of myelinated axons was compared to the number present in _ normal control sural nerve, at 4 weeks, the average number of myelinated axons regenerated across the saline filled channel was 12% of control sural nerve, 13% of control nerve for AgPlain filled rhAnnPl~ and 40% of control sural nerve for AgCDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) filled rhAnnPlc Transected rat dorsal roots regenerate across a 4 mm gap after 4 weeks in semipermeable guidance rhAnnPls filled with agarose gels derivatized with LN
oligopeptides. This is in contrast to the limited regeneration obtained by earlier experiments in the same model (McCormack et al., J. ComP. Npnrol.~ 313, pp. 449-56 (1991) using rhAnnPl~ filled with saline only. Though there was no significant difference in the number of myelinated axons 0.5 cm into the nerve gap, chAnnPl~ filled with CDPGYIGSR (CysAspProGly ~9449~ ~.

TyrIleGlySerArg; SEQ ID N0:1) derivatized agarose gels had significantly greater myelinated axons at the mid point of the channel compared to rhAnn~lc filled with agarose plain. This observation suggests a faster rate of nerve regeneration in gels derivatized with the CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) compared to AgPlain gels.
The number of myelinated axons at the midpoint of the channel in underivatized agarose gels was comparable to the number obtained in the saline filled channels of McCormack. This demonstrates that agarose gels are not inhibitory to regeneration in semipermeable channels as some other matrices like Matrigel~ have been shown to be. See, e.g., Valentini et al., EXP. ~eurol., 98, pp. 350-56 (1987). CDPGYIGSR
(CysAspProGlyTyrIleGlySerArg; SEQ ID N0:1) derivatized agarose gels also have a higher density of myelinated axons in the regenerated cable compared to underivatized agarose gels at 0.5 and 2.0 mm nerve gap points. This observation coupled with the data on numbers of myelinated axons along the channel, indicates that there is lesser fibrotic tissue per cable area in the derivatized agarose gels compared to underivatized AgPlain gels.
The doughnut shape of the regenerated cable at the midpoint of the channel points to possible syneresis of the agarose gels due to cellular activity in the regeneration environment.
All of the 10 mm long guidance rh~nn~l c across the 8 mm sural nerve gap were kinked distal to the point 2 mm into the nerve gap because of the channel was located across the knee-joint of the rat.
However, at the 2 mm point, both the number and density of myelinated axons were greater in rh~nn~lc filled with CDPGYIGSR-derivatized ~ W096/02286 ~ g~ 3 P~ &~

(CysAspProGlyTyrIleGlySerArg; SEQ ID NO:1) agarose compared to rhAnnPlc filled with underivatized agarose or saline.
Therefore in both the dorsal root model and in the more peripheral sural nerve model, CDPGYIGSR-derivatized (CysAspProGlyTyrIleGlySerArg; SEQ ID NO:1) agarose rhAnnPl~ had greater numbers of myelinated axons in higher densities per cable area compared to rhAnnPl~ filled with underivatized agarose or saline filled rhAnnol~.
This data indicates the feasibility of developing a matrix designed to enhance nerve regeneration by coupling neurite promoting biomolecules to agarose hydrogels.

W 0 96~2286 ~ DL _ 2~94493 SE~E L~;

(i) A ~ C~trn7Y~rq ~;~ In~
~ LE CF IN~IDCDoN: Ul__blll~i AND MEIHCrS E IR A

(iii) N~ 3R oF S~IE3~ES: 4 (iV) ~L~:2~ A ~ :
~AI A ~ : James F. Haley, Jr. , FI9~ & NFAVE
Bj Sl}a3Er: 1251 A~e. cf the A~E~iu;as ~C~ C~: N~ Ya~c rD, S~E: N~ Y~
E C~UNIRY: UEA
~F,I ZIP: 10020-I104 (v) a~3ER REP~E F~:
(A) ~EIInl~ IYPE: F1L~Y dlsk (B) CCPE~JLER: I3~ PC crnF~ hLe p~) SLE~ RE: EbtE~T:~n RP1P~ #1.0, ~3~ n #1.25 (vi) a~lI Al~l ,1~ N
(A) Al'U ,1 ~ /~ I .' N Nt~:
(B) P~ IY~E:
(C~ CIP~'LC:..L~N:
(Vii) E~ Al~l ,1~ N ~ A:
(A) AU~ .1~ N NlII3ER: US 08/280,646 (B) EII;IN~ ~IE: 20~ULY-1994 (ViiL) All ~ lEY/A~;ENr LhI~U~-~L~1:
(A) N~E: Haley Jr., James F.
pB) KW.I~ " N NUYeER: 27,794 (C~ ::EE~=D:~$~3CKer NUMeER: CII-26 PEr (iX) LLL~l~lNL~lA~ LN~u~.LL~N-(A) IFIE~HCNE: (212) 596-9000 ~B) IEI~3~X: (212) 556,9090 (2) LN~U~ LUN FOR SE2 D ND:l:
(i) Sl~E~d3E ~r~ri~
(A) IENI~H: 9 amina ~ri~c pB) TYPE: amin~ ac~
(q .qTR~NnFrNFc~ sin~le P~) l~y: lir~

~ WO 96102286 21 9 4 ~ 9 3 r~

(iii) ~W~AL: ~) (iv) ANrI~~: ~D

(Xi) ~: ~..JN: SE~2 D ~D:l:
~ R~ Gly I~r Ile Gly ~r Arg (2) INtU~. .l~N ~ SE~2 ~D 1~:2:

(A) IEI~I: 6 ar~ir~ z~s ~3) ~:: ~n~ ~i~
~) ~:

(iv) P.Nll~ENSE: ~:) (xi) SE~ ~l'lLN: 5~2 ID ~:2:
Gly A~q Gly P~ S ~ R~

(2) ~ U~.~l~N ~ SE~ ~ ID:3:

(C) ~Y~ l N~'i- ~rgle (D) IOE~Y: ~ir~

(iv) ANrI~E: 1 WO 96102286 2 1 9 ~ 4 9 3 i . P~

~ 48 ~

A~ A~) ~y (2) lNtU~..Ll~l E~ ~Fr') ~ N~:4:

(A) IIN: 5 amil~ ~it~
(B) TYPE: ~iro O ~ 3 (iv) P~rI~E: ~

(~) ~ l~ll~N: SE12 D N:~:4:
Gly ~y Gly Gly Gly

Claims (23)

WE CLAIM:
1. A bioartificial 3-D hydrogel extracellular matrix wherein the hydrogel is derivatized with at least one ECM adhesion molecule or adhesive peptide fragment thereof.
2. The matrix according to claim 1 wherein the hydrogel is derivatized with a peptide fragment selected from the group consisting of an RGD-containing sequence (ArgGlyAsp; AA2-AA4 of SEQ ID NO:2), a YIGSR-containing sequence (TyrIleGlySerArg; AA5-AAg of SEQ ID
NO:1), an IKVAV-containing sequence (IleLysValAlaVal;
AA11-AA15 of SEQ ID NO:3), and a combination of any of the foregoing sequences.
3. The matrix according to claim 2 wherein the hydrogel is derivatized with the sequence CDPGYISR
(CysAspProGlyTyrIleGlySerArg; SEQ ID NO:1).
4. The matrix according to claim 2 wherein the hydrogel is derivatized with the sequence GRGDSP
(GlyArgGlyAspSerPro; SEQ ID NO:2).
5. The matrix according to claim 2 wherein the hydrogel is derivatized with the sequence CSRARKQAASIKVAVSADR (CysSerArgAlaArgLysGln AlaAlaSerIleLysValAlaValSerAlaAspArg; SEQ ID NO:3).
6. The matrix according to any one of claims 1-5 wherein the hydrogel is a polysaccharide.
7. The matrix according to claim 6 wherein the hydrogel is agarose.
8. The matrix according to claim 7, wherein the agarose concentration ranges between 0.5-1.25%
(w/v) and the average gel pore radius is greater than 120 nm.
9. The matrix according to claim 8, wherein the agarose concentration is approximately 1.0% (w/v) and the average gel pore radius is approximately 150 nm.
10. A nerve guidance channel for use in regenerating a severed nerve, comprising:
a) a tubular, biocompatible, semi-permeable membrane, said membrane having openings adapted to receive the ends of the severed nerve, and an inner lumen through which the nerve may regenerate, and b) a bioartificial 3-D hydrogel extracellular matrix disposed in the lumen of the semi-permeable membrane, wherein the hydrogel is derivatized with at least one ECM adhesion molecule involved in neural cell adhesion, or adhesive peptide fragment thereof.
11. The nerve guidance channel of claim 10 wherein the adhesive peptide fragment is a peptide sequence selected from the group consisting of an RGD-containing sequence (ArgGlyAsp; AA2-AA4 of SEQ ID
NO:2), a YIGSR-containing sequence (TyrIleGlySerArg;
AA5-AA9 of SEQ ID NO:1), an IKVAV-containing sequence (IleLysValAlaVal; AA11-AA15 of SEQ ID NO:3), and a combination thereof.
12. The nerve guidance channel according to claim 11 wherein the hydrogel is derivatized with the sequence CDPGYIGSR (CysAspProGlyTyrIleGlySerArg; SEQ ID
NO:1).
13. The nerve guidance channel according to claim 11 wherein the hydrogel is derivatized with the sequence GRGDSP (GlyArgGlyAspSerPro; SEQ ID NO:2).
14. The nerve guidance channel according to claim 11 wherein the hydrogel is derivatized with the sequence CSRARKQAASIKVAVSADR (CysSerArgAlaArgLysGln AlaAlaSerIleLysValAlaValSerAlaAspArg; SEQ ID NO:3).
15. The nerve guidance channel according to any one of claims 10-14 wherein the hydrogel is a polysaccharide.
16. The nerve guidance channel according to claim 15 wherein the hydrogel is agarose.
17. The nerve guidance channel according to claim 16 wherein the agarose concentration ranges between 0.5-1.25% (w/v) and the average gel pore radius is greater than 120 nm.
18. The nerve guidance channel according to claim 16 wherein agarose concentration is approximately 1% and the average gel pore radius is approximately 150 nm.
19. A method for promoting in vivo regeneration of a severed nerve comprising securing the proximal and distal ends of the severed nerve into each end of a tubular nerve guidance channel according to any one of claims 10-18.
20. A method for promoting in vivo tissue replacement comprising suspending cells in a hydrogel matrix according to any one of claims 1-9 to form a cell-seeded hydrogel matrix, and implanting the cell-seeded hydrogel matrix into a suitable implantation site in a host.
21. The method according to claim 20 wherein the cell-seeded matrix is cultured in vitro prior to implantation in the host.
22. A method for promoting in vivo tissue regeneration comprising implanting a hydrogel matrix according to any one of claims 1-9 into a suitable implantation site in a host.
23. A method for controlling the metabolic function of transplanted cells upon in vivo implantation in a host, comprising:
a) suspending cells in a bioartificial extracellular matrix according to any one of claims 1-7 form a cell-seeded matrix;
b) encapsulating the matrix in a semi-permeable membrane to form a bioartificial organ;
c) implanting the bioartificial organ into a suitable implantation site in a host.
CA002194493A 1994-07-20 1995-07-20 Compositions and methods for a bioartificial extracellular matrix Abandoned CA2194493A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/280,646 1994-07-20
US08/280,646 US5834029A (en) 1994-07-20 1994-07-20 Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment

Publications (1)

Publication Number Publication Date
CA2194493A1 true CA2194493A1 (en) 1996-02-01

Family

ID=23073997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002194493A Abandoned CA2194493A1 (en) 1994-07-20 1995-07-20 Compositions and methods for a bioartificial extracellular matrix

Country Status (14)

Country Link
US (2) US5834029A (en)
EP (1) EP0772466B1 (en)
JP (1) JPH10503098A (en)
KR (1) KR970704481A (en)
AT (1) ATE255425T1 (en)
AU (1) AU3142395A (en)
CA (1) CA2194493A1 (en)
DE (1) DE69532240D1 (en)
FI (1) FI970218A (en)
IL (1) IL114672A (en)
NO (1) NO970155L (en)
TR (2) TR199500883A2 (en)
WO (1) WO1996002286A1 (en)
ZA (1) ZA956033B (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
SE9601243D0 (en) * 1996-03-29 1996-03-29 Hans Arne Hansson Promotion of regeneration of organized tissues
IL118376A0 (en) * 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
SE9602879D0 (en) * 1996-07-26 1996-07-26 Henrich Cheng Medical device
US6238429B1 (en) * 1997-05-05 2001-05-29 Medtronic, Inc. Biologic cabling
JP4988076B2 (en) * 1997-05-22 2012-08-01 マイヤー,ヤールク Peptide-coated implant and method for preparing the same
AU3097999A (en) * 1998-03-18 1999-10-11 University Of Pittsburgh Chitosan-based composite materials containing glycosaminoglycan for cartilage repair
US6171610B1 (en) * 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6027744A (en) * 1998-04-24 2000-02-22 University Of Massachusetts Medical Center Guided development and support of hydrogel-cell compositions
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6592623B1 (en) 1999-08-31 2003-07-15 Virginia Commonwealth University Intellectual Property Foundation Engineered muscle
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) * 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
DE10026789B4 (en) * 2000-05-31 2004-09-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Cartilage replacement and process for its manufacture
JP2002078792A (en) * 2000-09-07 2002-03-19 Kuraray Co Ltd Material for nerve regeneration
DE10053611A1 (en) * 2000-10-28 2002-05-02 Inst Textil & Faserforschung Bioresorbable nerve guide
WO2002057428A1 (en) * 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
CA2428748A1 (en) * 2000-11-14 2002-05-23 N.V.R. Labs Bvi Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
DE10105040A1 (en) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide derivatives for the treatment of post-lesion diseases of the nervous system
DE10105041A1 (en) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
US20050192228A1 (en) * 2001-02-05 2005-09-01 Jean Rapin Tripeptide derivatives for the treatment of neurodegenerative diseases
DE10105038B4 (en) * 2001-02-05 2005-07-07 Neurotell Ag Tripeptide derivatives for the treatment of postläsional diseases of the nervous system
WO2002062961A2 (en) * 2001-02-06 2002-08-15 Massachusetts Institute Of Technology Peptide scaffold encapsulation of tissue cells and uses thereof
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040151705A1 (en) * 2002-03-22 2004-08-05 Shuichi Mizuno Neo-cartilage constructs and a method for preparation thereof
JP3871525B2 (en) * 2001-04-26 2007-01-24 ニプロ株式会社 Biological tissue or organ regeneration device
US20030049839A1 (en) * 2001-08-01 2003-03-13 The University Of Texas System Transparent multi-channel cell scaffold that creates a cellular and/or molecular gradient
US6716225B2 (en) * 2001-08-02 2004-04-06 Collagen Matrix, Inc. Implant devices for nerve repair
AU2002335824A1 (en) * 2001-10-12 2003-04-22 Case Western Reserve University Neuronal regeneration
US7041506B2 (en) * 2001-11-19 2006-05-09 Becton Dickinson And Company Peptides promoting cell adherence, growth and secretion
AU2002351164A1 (en) * 2001-11-26 2003-06-10 Molecular Reflections, Inc. Microscale immobilization of molecules using a hydrogel and methods of use thereof
US7429267B2 (en) * 2001-12-04 2008-09-30 The Trustees Of The University Of Pennsylvania Device and method using integrated neuronal cells and an electronic device
KR100493461B1 (en) * 2002-02-27 2005-06-07 재단법인서울대학교산학협력재단 Natural polymers bonded adhesion molecular, their preparation and their use
US8298606B2 (en) * 2002-03-08 2012-10-30 The Regents Of The University Of California Methods and compositions for stabilizing the myocardium
US6932833B1 (en) * 2002-04-01 2005-08-23 Bobby W. Presley Method and barrier for limiting fluid movement through a tissue rent
US20070100358A2 (en) * 2002-08-01 2007-05-03 Texas Scottish Rite Hospital For Children A Biomimetic Synthetic Nerve Implant
WO2005046457A2 (en) * 2003-11-05 2005-05-26 Texas Scottish Rite Hospital For Children A biomimetic biosynthetic nerve implant
US20060034807A1 (en) * 2002-08-09 2006-02-16 Ottawa Health Research Institute Innervated artificial tissues and uses thereof
JP4571776B2 (en) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 Lubricating oil composition
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
JP4605985B2 (en) * 2002-12-27 2011-01-05 ニプロ株式会社 Nerve regeneration induction tube
CN102367277B (en) 2003-01-31 2014-04-09 比奥根艾迪克Ma公司 Polymer conjugates of mutated neublastin
US20040156878A1 (en) * 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
ATE433759T1 (en) 2003-04-18 2009-07-15 Biogen Idec Inc POLYMER CONJUGATED GLYCOSILATED NEUBLASTIN
WO2005014784A2 (en) * 2003-06-20 2005-02-17 Tumer Tumay O System for molecular imaging
US8545386B2 (en) * 2003-08-14 2013-10-01 Boston Scientific Scimed, Inc. Surgical slings
WO2005020677A1 (en) 2003-08-29 2005-03-10 The Walter And Eliza Hall Institute Of Medical Research Method of selecting animal models from animals which have been subject to mutagenesis, and the use of myb transcription factors for screening
JP2007516984A (en) 2003-12-24 2007-06-28 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ Therapeutic substances and uses therefor
US7709439B2 (en) * 2004-02-20 2010-05-04 Boston Scientific Scimed, Inc. Biomaterials for enhanced healing
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
GB0405045D0 (en) * 2004-03-05 2004-04-07 Spinox Ltd Composite materials
US20060134779A1 (en) * 2004-03-10 2006-06-22 Banes Albert J Modulation of cell intrinsic strain to control cell modulus, matrix synthesis, secretion, organization, material properties and remodeling of tissue engineered constructs
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
JP4980211B2 (en) 2004-05-12 2012-07-18 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ Cell isolation method
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
WO2006019649A1 (en) * 2004-07-15 2006-02-23 Dentigenix Inc. Mineralizing composite materials for restoring teeth
US8722862B2 (en) 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
BRPI0514534A (en) 2004-08-19 2008-06-17 Biogen Idec Inc neublastin variants
WO2006030182A2 (en) * 2004-09-14 2006-03-23 Neurotex Limited Methods and apparatus for enhanced growth of peripheral nerves and nervous tissue
US20060079927A1 (en) * 2004-10-08 2006-04-13 Medtronic Vascular, Inc., A Delaware Corporation Detachable joint catheter and method
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
ES2490610T3 (en) * 2004-12-08 2014-09-04 Shire Regenerative Medicine, Inc. Materials and methods for minimally invasive administration of a fluid composition containing cells
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US8874204B2 (en) 2004-12-20 2014-10-28 Cardiac Pacemakers, Inc. Implantable medical devices comprising isolated extracellular matrix
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
WO2006112932A2 (en) * 2005-02-17 2006-10-26 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices containing attractants for endothelial cells
US8017139B2 (en) 2005-02-23 2011-09-13 Zimmer Technology, Inc. Blend hydrogels and methods of making
US7851189B2 (en) * 2005-03-07 2010-12-14 Boston Scientific Scimed, Inc. Microencapsulated compositions for endoluminal tissue engineering
ATE470701T1 (en) * 2005-04-21 2010-06-15 Massachusetts Inst Technology MATERIALS AND METHODS FOR ALTERING AN IMMUNE RESPONSE TO EXOGENE AND ENDOGENE IMMUNOGENES, INCLUDING GENIDENTIC AND NON-GENIDENTIC CELLS, TISSUES OR ORGANS
CN102743792B (en) 2005-06-21 2014-09-24 夏尔再生医学公司 Methods and compositions for enhancing vascular access
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
DE102005040816A1 (en) * 2005-08-29 2007-03-15 Skh-Gmbh Preparing capillary-structured neural implant, useful for regenerating degenerated neural tissue, comprises contacting sodium alginate sol with multivalent cation solution and forming thin membrane in boundary region between two liquids
US8921109B2 (en) 2005-09-19 2014-12-30 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US20070190165A1 (en) * 2005-10-21 2007-08-16 Brey Eric M Tissue-specific basement membrane gels
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
AU2006321809A1 (en) 2005-12-07 2007-06-14 Zimmer, Inc. Methods of bonding or modifying hydrogels using irradiation
JP2007177244A (en) 2005-12-22 2007-07-12 Zimmer Inc Perfluorocyclobutane crosslinked hydrogel
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
US8092818B2 (en) * 2006-05-17 2012-01-10 Boston Scientific Scimed, Inc. Medical devices having bioactive surfaces
US7625552B2 (en) * 2006-05-30 2009-12-01 Boston Scientific Scimed, Inc. Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces
WO2007147014A2 (en) * 2006-06-13 2007-12-21 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
EP2051726B1 (en) 2006-07-18 2018-04-18 University of Utah Research Foundation Methods for treating pain and screening analgesic compounds
JP4569543B2 (en) * 2006-08-18 2010-10-27 ニプロ株式会社 Precursor for tissue regeneration device with swellable rod
EP2452700B1 (en) * 2006-09-06 2013-10-16 Boston Scientific Limited Medical devices having a coating for promoting endothelial cell adhesion
EP2086601A2 (en) * 2006-11-06 2009-08-12 Bonwrx, Inc. Nerve regeneration device
CN103230414A (en) * 2006-11-07 2013-08-07 夏尔再生医学公司 Materials and methods for treating and managing angiogenesis-mediated diseases
US20100291180A1 (en) * 2007-02-20 2010-11-18 Uhrich Kathryn E Nerve guidance tubes
WO2008112163A1 (en) * 2007-03-09 2008-09-18 Corning Incorporated Gum coatings for cell culture, methods of manufacture and methods of use
JP2010520766A (en) * 2007-03-09 2010-06-17 コーニング インコーポレイテッド Three-dimensional gum matrix for cell culture, production method and method of use
CA2680886A1 (en) * 2007-03-15 2008-09-18 Boston Scientific Limited Methods to improve the stability of cellular adhesive proteins and peptides
WO2008121331A1 (en) * 2007-03-30 2008-10-09 Pervasis Therapeutics, Inc. Materials and methods for treating nerve damage and promoting nerve repair and regeneration
US20100211172A1 (en) * 2007-04-02 2010-08-19 Georgia Tech Research Corporation Implantable Device For Communicating With Biological Tissue
NZ580947A (en) 2007-05-01 2012-05-25 Biogen Idec Inc Compositions and methods for increasing vascularization
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US9421304B2 (en) 2007-07-03 2016-08-23 Histogenics Corporation Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant
US7731988B2 (en) 2007-08-03 2010-06-08 Zimmer, Inc. Multi-polymer hydrogels
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US8062739B2 (en) 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US20090104244A1 (en) * 2007-09-21 2009-04-23 Boston Scientific Scimed, Inc. Therapeutic agent-eluting medical devices having textured polymeric surfaces
US20090082856A1 (en) * 2007-09-21 2009-03-26 Boston Scientific Scimed, Inc. Medical devices having nanofiber-textured surfaces
US20100278798A1 (en) * 2007-09-27 2010-11-04 The Trustees Of Columbia University In The City Of New York Methods and systems for forming biocompatible materials
US7947784B2 (en) 2007-11-16 2011-05-24 Zimmer, Inc. Reactive compounding of hydrogels
WO2009086535A2 (en) * 2007-12-27 2009-07-09 The Trustees Of Columbia University In The City Of New York Systems and methods for forming patterned extracellular matrix materials
US8034362B2 (en) 2008-01-04 2011-10-11 Zimmer, Inc. Chemical composition of hydrogels for use as articulating surfaces
WO2009108760A2 (en) * 2008-02-26 2009-09-03 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US20090297581A1 (en) * 2008-05-28 2009-12-03 Boston Scientific Scimed, Inc. Medical devices having electrodeposited coatings
WO2009158325A2 (en) * 2008-06-25 2009-12-30 Boston Scientific Scimed, Inc. Medical devices having surface coatings
US20090324685A1 (en) * 2008-06-26 2009-12-31 Boston Scientific Scimed, Inc. Medical device coatings containing charged materials
WO2010074958A1 (en) * 2008-12-22 2010-07-01 The Trustees Of The University Of Pennsylvania Hydrolytically degradable polysaccharide hydrogels
US8574612B2 (en) * 2009-03-04 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having a coating of biologic macromolecules
CA2769188C (en) * 2009-09-02 2019-02-12 Lifecell Corporation Vascular grafts derived from acellular tissue matrices
EP2482828B1 (en) 2009-10-02 2014-12-17 Baxter International Inc Hematopoietic stem cells for use in the treatment of a kidney injury
CN106913902A (en) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 Polysaccharide based aquagel
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
IN2012DN05181A (en) 2009-11-12 2015-10-23 Vbi Technologies Llc
WO2011068778A1 (en) * 2009-12-03 2011-06-09 Lifecell Corporation Nerve treatment devices and methods
EP2575909B1 (en) 2010-06-03 2020-01-15 Technology Innovation Momentum Fund (Israel) Limited Partnership Malleable hydrogel hybrids made of self-assembled peptides and biocompatible polymers and uses thereof
JP6042815B2 (en) 2010-10-08 2016-12-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US9486404B2 (en) 2011-03-28 2016-11-08 The Trustees Of The University Of Pennsylvania Infarction treatment compositions and methods
ES2675307T3 (en) 2011-12-22 2018-07-10 Centre Hospitalier Universitaire Vaudois (Chuv) Selective plasma activation for medical implants and wound healing devices
WO2013126590A2 (en) 2012-02-21 2013-08-29 Baxter International Inc. Pharmaceutical composition comprising cd34+ cells
CN103542082B (en) * 2012-07-16 2016-04-27 鸿富锦精密工业(深圳)有限公司 Gear drive and mechanical arm linkage structure
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
CA2913993A1 (en) 2013-05-31 2014-12-04 University Of Utah Research Foundation Conotoxin peptides, pharmaceutical compositions and uses thereof
EP3052083A4 (en) * 2013-09-30 2017-05-03 Bioactive Regenerative Therapeutics, Inc. Biomimetic hybrid gel compositions and methods of use
US20160251646A1 (en) * 2013-10-12 2016-09-01 Innovative Surface Technologies, Inc. Tissue scaffolds for electrically excitable cells
US20150141786A1 (en) * 2013-11-15 2015-05-21 Case Western Reserve University Interfacing With The Peripheral Nervous System (PNS) Using Targeted Fascicular Interface Device
US20150182673A1 (en) 2013-12-30 2015-07-02 Boston Scientific Scimed, Inc. Functionalized lubricious medical device coatings
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
CN108884135B (en) 2015-10-27 2024-03-26 昆士兰大学 Therapeutic methods and agents useful therein
WO2018022553A1 (en) 2016-07-25 2018-02-01 Cerapedics, Inc. Peptide-coated calcium phosphate particles
US11150251B2 (en) 2016-10-07 2021-10-19 Clemson University Research Foundation Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495288A (en) * 1981-03-13 1985-01-22 Damon Biotech, Inc. Method of culturing anchorage dependent cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5019087A (en) * 1986-10-06 1991-05-28 American Biomaterials Corporation Nerve regeneration conduit
US5030225A (en) * 1987-03-13 1991-07-09 Brown University Research Foundation Electrically-charged nerve guidance channels
US5092871A (en) * 1987-03-13 1992-03-03 Brown University Research Foundation Electrically-charged nerve guidance channels
FR2616318A1 (en) * 1987-06-15 1988-12-16 Centre Nat Rech Scient ARTIFICIAL SKIN AND PROCESS FOR PREPARING THE SAME
US5147797A (en) * 1987-08-25 1992-09-15 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5294551A (en) * 1987-08-25 1994-03-15 Regents Of The University Of Minnesota Cell culture substrate coated with polypeptides having fibronectin activity
US5171271A (en) * 1987-08-25 1992-12-15 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
SE8703625D0 (en) * 1987-09-18 1987-09-18 Kabivitrum Ab NEW MEDICAL USE
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5011486A (en) * 1988-11-18 1991-04-30 Brown University Research Foundation Composite nerve guidance channels
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5026381A (en) * 1989-04-20 1991-06-25 Colla-Tec, Incorporated Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit
US4963146A (en) * 1989-04-20 1990-10-16 Colla-Tec Incorporated Multi-layered, semi-permeable conduit for nerve regeneration
US5354736A (en) * 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5330911A (en) * 1989-09-28 1994-07-19 Board Of Regents, The University Of Texas System Surfaces having desirable cell adhesive effects
US5082926A (en) * 1989-12-14 1992-01-21 Regents Of The University Of Minnesota Polypeptide with type iv collagen cell adhesion, spreading and motility activity
US5081031A (en) * 1989-12-14 1992-01-14 Regents Of The University Of Minnesota Synthetic polypeptide with type iv collagen activity
AU8649391A (en) * 1990-08-15 1992-03-17 University Of Miami Autotransplantation of schwann cells to promote nervous system repair
AU666118B2 (en) * 1991-04-25 1996-02-01 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
CA2113118C (en) * 1991-07-08 2002-09-17 Samuel Weiss Novel growth factor-responsive progenitor cells which can be proliferated in vitro
CA2124190A1 (en) * 1991-11-26 1993-06-10 Saleh M. Shenaq Fetal membrane tubes for nerve and vessel grafts
EP0673259A4 (en) * 1992-01-23 1995-12-06 Univ New York A method for transplanting cells into the brain and therapeutic uses therefor.
US5279966A (en) * 1992-04-02 1994-01-18 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of a novel secreted protein, F-spondin
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment

Also Published As

Publication number Publication date
IL114672A (en) 2000-12-06
DE69532240D1 (en) 2004-01-15
ZA956033B (en) 1996-03-11
NO970155D0 (en) 1997-01-14
EP0772466A1 (en) 1997-05-14
IL114672A0 (en) 1995-11-27
JPH10503098A (en) 1998-03-24
TR199500883A2 (en) 1996-06-21
TR199500884A2 (en) 1996-06-21
EP0772466B1 (en) 2003-12-03
US6156572A (en) 2000-12-05
ATE255425T1 (en) 2003-12-15
FI970218A0 (en) 1997-01-17
FI970218A (en) 1997-03-17
US5834029A (en) 1998-11-10
WO1996002286A1 (en) 1996-02-01
KR970704481A (en) 1997-09-06
NO970155L (en) 1997-03-19
AU3142395A (en) 1996-02-16

Similar Documents

Publication Publication Date Title
US5834029A (en) Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
Mosahebi et al. A novel use of alginate hydrogel as Schwann cell matrix
Tang et al. The effects of gradients of nerve growth factor immobilized PCLA scaffolds on neurite outgrowth in vitro and peripheral nerve regeneration in rats
Bellamkonda et al. Tissue engineering in the nervous system
KR100377520B1 (en) Implantable Acrylamide Copolymer Hydrogel
WO2014133027A1 (en) Hydrogel
Salehi et al. Polyurethane/gelatin nanofibrils neural guidance conduit containing platelet-rich plasma and melatonin for transplantation of schwann cells
Yan et al. Use new PLGL-RGD-NGF nerve conduits for promoting peripheral nerve regeneration
US9421229B2 (en) Neural scaffolds
JP6118905B2 (en) New scaffold for cardiac repair patches
US20180303974A1 (en) Compositions for regeneration and repair of neural tissue
JP2006506110A (en) Aggregated coprecipitates of sulfated polysaccharides and fibrous proteins and uses thereof
Gentile et al. Polymer science for macroencapsulation of cells for central nervous system transplantation
Schackel et al. Peptides and astroglia improve the regenerative capacity of alginate gels in the injured spinal cord
US20040235161A1 (en) Artificial kidney having function of metabolizing protein and method of constructing the same
WO2003026489A2 (en) Biopolymer and biopolymer-cell compositions for nerve tissue repair
Mey et al. Electrospun fibers as substrates for peripheral nerve regeneration
RU2517117C2 (en) Method for stimulating neurotisation using nanostructured matrix and genetic constructs
Guarino et al. Bioinspired scaffolds for bone and neural tissue and interface engineering
Musuc et al. Therapeutic polymer gel system in neural tissue engineering
Stokols The design, fabrication, and in vivo testing of biopolymer-based nerve guidance scaffolds for spinal cord injury
Günther et al. Hydrogel biomaterials in spinal cord repair and regeneration
Kokai Controlled delivery systems for neuronal tissue engineering
Wen Studies in the development of a bridging device for guiding regenerating axons
Bellamkonda Development of a three-dimensional extracellular matrix equivalent for neural cells and nerve regeneration

Legal Events

Date Code Title Description
FZDE Discontinued